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Abstract
Inappropriate activation of the NOTCH signaling pathway, e.g. by activating mu-
tations, contributes to the pathogenesis of various human malignancies. Using
a bottom up approach based on the acquisition of high–dimensional microarray
data of classical Hodgkin lymphoma (cHL) and non-Hodgkin B cell lymphomas
as control, we identify a cHL specific NOTCH gene-expression signature domi-
nated by the NOTCH co-activator Mastermind-like 2 (MAML2). This set the
basis for demonstrating that aberrant expression of the essential NOTCH co-
activator MAML2 provides an alternative mechanism to activate NOTCH signal-
ing in human lymphoma cells. Using immunohistochemistry we detected high-level
MAML2 expression in several B cell-derived lymphoma types, including cHL cells,
whereas in normal B cells no staining for MAML2 was detectable. Inhibition of
MAML protein activity by a dominant negative form of MAML or by shRNAs
targeting MAML2 in cHL cells resulted in down-regulation of the NOTCH target
genes HES7 and HEY1, which we identified as overexpressed in cHL cells, and
in reduced proliferation. In order to target the NOTCH transcriptional complex
directly we developed short peptide constructs that competitively inhibit NOTCH
dependent transcriptional activity as demonstrated by NOTCH reporter assays
and EMSA analyses. We conclude that NOTCH signaling is aberrantly activated
in a cell autonomous manner in cHL. This is mediated by high-level expression
of the essential NOTCH co-activator MAML2, a protein that is only weakly ex-
pressed in B cells from healthy donors. Using short peptide constructs we moreover
show, that this approach is promising in regard to the development of NOTCH
pathway inhibitors that will also work in NOTCH associated malignancies that
are resistant to γ-secretase inhibition.
ii
Zusammenfassung
Die aberrante Aktivierung des NOTCH Signalweges, welche zum Beispiel durch
aktivierende Mutationen der NOTCH-Rezeptoren hervorgerufen wird, trägt ent-
scheidend zu verschiedensten malignen Erkrankungen im Menschen bei. Basierend
auf der Analyse von hochdimensionalen Microarray-Datensätzen von klassischen
Hodgkin Lymphoma Fällen und nicht-Hodgkin Fällen, haben wir eine Hodgkin
Lymphoma-spezifische NOTCH Signatur identifiziert. Diese wird von dem essen-
tiellen NOTCH-Koaktivator Mastermind-like 2 (MAML2) signifikant dominiert.
Auf der Grundlage dieses Resultates haben wir die Rolle von MAML2 im Kontext
des Hodgkin Lymphoma-spezifischen, aberrant re-gulierten NOTCH Signalweges
weiter untersucht. Die signifikante Überexpression von MAML2 im Hodgkin Lym-
phom konnte in verschiedenen Hodgkin Lymphom Zelllinien und auch durch die
immunhistochemische Analyse von primären Hodgkin Lymphom Fällen verifiziert
werden. Mit Hilfe des Knockdowns von MAML2 bzw. der Inhibition des NOTCH
Signalweges durch die Verwendung einer kompetitiv, dominant-negativ wirken-
den, trunkierten Variante von MAML1 konnte daraufhin gezeigt werden, dass die
Überexpression von MAML2 der limitierende Faktor für die Hodgkin Lymphoma-
spezifische, pathologische Deregulation des NOTCH Signalweges ist. Die MAML2-
vermittelte Überaktivierung des NOTCH Signalweges ist darüber hinaus essentiell
für die Proliferation von Hodgkin Lymphom Zelllinien und die aberrante Expres-
sion der NOTCH Zielgene HES7 und HEY1. Das konstitutive Vorhandensein von
aktiviertem, intrazellulären NOTCH1 in Hodgkin Lymphom Zelllinien impliziert
darüber hinaus, dass der Signalweg im Hodgkin Lymphom zellautonom aktiviert
ist. Weiterhin wurde der NOTCH-Transkriptionelle-Komplex (NTK) somit als po-
tentielles therapeutisches Ziel identifiziert. Zum Zwecke der Inhibition der NTK-
Assemblierung wurden kurze, MAML1-basierte Peptid-Konstrukte entwickelt. Mit
Hilfe von NOTCH-spezifischen Reporterassays und EMSA-Analysen konnte ge-
zeigt werden, dass in vitro effektiv die NTK-Assemblierung und NTK-abhängige
transkriptionelle Aktivierung durch diese Peptid-Konstrukte inhibiert wird.
In dieser Arbeit wird damit ein neuer, pathologisch hochwirksamer Mechanis-
mus der NOTCH Signalweg-Deregulation aufgedeckt. Gleichzeitig wird mit der
Entwicklung NOTCH-inhibitorisch wirksamer Peptid-Konstrukte eine Möglichkeit
aufgezeigt, diesen Mechanismus in dem essentiellsten Schritt, nämlich der NTK-
Assemblierung, zu inhibieren. Dies ist eine Herangehensweise, die auch bei anderen
malignen Erkrankungen mit pathologischer Deregulation des NOTCH-Signalweges
als Ursache wirksam sein könnte, insbesondere bei solchen, bei denen sich die Be-
handlung mit γ-Sekretase Inhibitoren als nicht wirksam erweist.
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1 Introduction
1.1 Hodgkin Lymphoma
1.1.1 Historical view on Hodgkin Lymphoma
As early as in 1832, the British physician Thomas Hodgkin published an article de-
scribing findings of the dissection of seven people showing ’Morbid Appearances of the
Absorbent Glands and Spleen’. He reported, that these people suffered from massive
enlargement of the spleen and the lymph nodes [1].
This was the first description of what was later to be called Hodgkin’s Disease or accord-
ing to the World Health Organization Hodgkin Lymphoma. Even though more than 150
years have passed since then, the aetiology of this malignancy has become explainable
only in the last few decades.
1.1.2 Epidemiology of classical Hodgkin lymphoma (cHL)
Hodgkin lymphoma is a very common type of lymphoma with an incidence of around
3 per 100,000 in Europe and the USA [2]. Most people affected from Hodgkin lym-
phoma are aged around 30 or 50 years, thus following a bimodal distribution. Men
are affected more often than women [3]. Interestingly, incidence of Hodgkin lymphoma
in developing countries is predominant during childhood and decreases with age [3].
Hodgkin lymphoma is divided into various subtypes. The nodular-sclerosing-, the mixed-
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(a) (b)
Figure 1.1: Defining a new disease, Thomas Hodgkin’s work in the early 19th century
A portrait (a) of Thomas Hodgkin and a picture (b) of what he found to be the Morbid Appearances
of seven patients he dissected in 1832. (a), Reproduced courtesy of Gordon Museum, Guy’s Hospital,
GKT, King’s College London. (b), Hodgkin’s disease watercolor drawing by Robert Carswell in 1828.
cellularity- and lymphocyte-depleted subtypes are summarized as classical Hodgkin lym-
phoma (cHL). The lymphocyte-predominant subtype (LP) presents a distinct entity. As
this work entirely focuses on cHL, no further description of the LP type will be provided.
Readers interested in this particular entity of Hodgkin lymphoma are referred to [4].
Aspects of inheritance
Various studies indicate, that cHL is one of the malignancies, in which a significant
association between cHL incidences and inheritance is to be assumed. One of these
studies found cHL to be number four in a ranking list of cancers with high familial
indices. Yet, the percentage of familial cHL of all cHL cases is very low and so far, no
genetic markers could be identified, that would mediate such an inheritance mechanism
[5].
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1.1.3 Treatment of cHL, prognosis and caveats today
Clinicians divide the advancement of Hodgkin lymphoma in three stages, each of with
different treatment regimens being used. Ongoing trials are trying to minimize the cycles
of chemotherapy and the dose of radio therapy. Below, some common forms of treatment
for each stage are listed as are percentages of survival rates from different studies.
• Early stage cHL, Engert et al. 2010 [6], treatment group 4: 2× chemotherapy
doxorubicin, vinblastine, bleomycin, dacarbazine, radio therapy 20Gy. 96.6% 5-
year overall survival.
• intermediate early-stage cHL study EORTC H9U: 6× chemotherapy with doxoru-
bicin, vinblastine, bleomycin and dacarbazine, radio therapy 30Gy. 95% 4-year
overall survival [7].
• advanced–stage cHL study GHSG HD12: 8× chemotherapy with bleomycin, etopo-
side, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone.
88% 4-year overall survival [8].
The treatment regimens used presently have a number of severe side effects. Some
acute side effects are for example myelosuppression with associated cytopenias and pul-
monary toxicity [9, 10]. Long term toxicities include secondary cancers as for example
Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) [11]. Studies
show, that the 20-25 year cumulative actuarial risk of secondary cancers after tradi-
tional cHL treatment is 24-28%, with the most common secondary malignancy being
breast-cancer [12, 13, 14, 15, 16]. There is a strong association of radio therapy with
the onset of these secondary malignancies, yet some of them are also seen when only
chemotherapy was applied [17].
Though, overall survival rates are high for patients treated with early–stage and inter-
mediate early–stage cHL, the prognosis for elderly and advanced stage patients is poor.
The overall survival rate with a follow up of seven years can be as low as 73% [18]. This
emphazises the importance of advancing treatment strategies for cHL to higher overall
survival rates at the same time reducing toxicity of treatment.
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1.1.4 Aetiology of cHL
The character of HRS cells
The special character of Hodgkin lymphoma cells was already observed around the year
1900 by Carl Sternberg [19] and Dorothy Reed [20]. Both discovered, that the mono-
nucleated Hodgkin cells and the multi-nucleated — and henceforth called — Reed–
Sternberg cells are hallmarks of the disease described by Thomas Hodgkin. In this work,
the two cell types will be summarized using the term Hodgkin–Reed–Sternberg (HRS)
cells. A prominent pathohistological marker of cHL is the expression of CD30 [21], a TNF
receptor family member (see figure 1.2). This marker is to some degree compromised
Figure 1.2: CD30 Staining of a lymph node from a cHL patient
CD30 staining is a typical histological cHL marker used by pathologists for cHL diagnosis. The
blackly stained, enlarged cHL cells make up just around 1% of the tumor tissue.
by some T cell lymphomas that also express CD30 (e.g. CD30+ anaplastic large T-
cell lymphoma [22]). HRS cells are unusually large in comparison to normal cells of
lymphatic origin and comprise usually about 1% of the tumor tissue [23]. The remaining
99% are composed of bystander cells that are attracted by signals given from the HRS
cells. This attraction will result in the cHL-typical, inflammatory microenvironment
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(for a thorough description, please see below). The rarity of HRS cells within the tumor
tissue and the difficulty to separate them from bystander cells add substantially to the
limitations of experimental characterisation, which is mainly done by the usage of HRS
cell lines established from cHL patients. However, using e.g. laser-dissection techniques,
it is nowadays also possible to isolate HRS cells from cHL patient biopsies which may
be used for experimental characterisation (see e.g. [24]).
The cellular origin of HRS cells
HRS cells show an immunophenotype that is difficult to interpret, as lineage markers
of several distinct lineages are found in these cells. However, in nearly all cases of cHL,
these cells are characterized by the presence of rearranged and somatically hypermutated
Ig variable genes [25]. As these rearrangements and hypermutations take place in ger-
minal center B cells, the cellular origin and the differentiation stage (where development
takes a turn to pathogenic events) of HRS cells was pinpointed to this particular B cell
population.
However, HRS cells do not show a B cell phenotype and have lost a considerable
part of the B cell specific gene expression pattern. In HRS cells a vast number of B
cell lineage genes is down–regulated, whereas a large set of B cell lineage inappropriate
genes is up–regulated [26, 27, 24].
Another aspect of the cellular origin of cHL is, that the tumor cells of a particular cHL
patient display the very same Ig variable rearrangements, indicating that they are the
clonal expansion of one original tumor cell [28, 29]. In 25% of cHL cases these mentioned
processes lead to non-functional Ig variable genes, a fact that would normally result in
apoptosis induction of the affected B cell. To evade apoptosis induction, HRS cells have
developed a number of mechanisms. For example, mutations of the FAS gene found
in cHL (yet only rarely) prevent apoptosis induction by FAS-ligands of effector cells.
Moreover, several anti-apoptotic genes such as c-FLIP [30] and Bcl-2 family proteins are
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expressed at aberrantly high levels in cHL [3].
There are also reports on cHL cases with a T-cell origin which, however, are very rare
[31]. These cases show no rearrangement of Ig variable genes nor their hypermutation,
yet carry T cell receptor gene rearrangements. Strikingly, those seemingly T cell derived
cases of cHL are very similar to B cell derived cHL as they cluster with B cell origin
cHL cases when their gene expression profiles are analyzed together with other B or T
cell associated malignancies [32].
The cHL microenvironment
As mentioned above, cHL is characterized by the infiltration of various cell types of
the immune system into lymphatic tissue. Cell types found in the microenvironment
are mast cells, B cells, T cells and plasma cells to name just a few. Presumably, these
cells are attracted through a number of cytokines (IL5, IL13, IL21) [33, 34, 35] and
chemokines (CCL5, CCL17, CCL22) [36, 37] which are secreted by the HRS cells. In
turn, the attracted cells seem to play an important role in the survival of HRS cells
as there is evidence that they provide appropriate survival signals (see table 1.1 and
[31]). This hypothesis is endorsed by the fact, that HRS cells are very difficult to grow
in culture, are basically not found in peripheral blood and even if they metastasize
into non-lymphoid tissue, they are embedded in their typical microenvironment [38, 31].
Hence, the cHL microenvironment is an important factor for the pathogenesis of this
malignancy in that it maintains an appropriate environment for the tumor cells and plays
a role in promoting tumor growth and immune escape [39]. A recent study additionally
indicates the presence of CD68+ macrophages in the tumor microenvironment in a subset
of cHL cases. When these cells are found in the cHL microenvironment, prognosis is
significantly poorer than when they are absent [40]. Table 1.1 shows, how a number of
survival signals is given to HRS cells by diverse types of immune system cells.
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HRS cells provide/secrete Attracted/interacting
cell/antigen
Secondary Effects
CD30 Eosinophil/CD30L possibly growth stimulation of cHL
[31]
IL5, CCL5, CCL28 Eosinophil possibly growth stimulation of cHL
TNFα, TNFβ Fibroblast Attraction of Eosinophils
PD1L, IL10, TGFβ, galectin1 CD8+ TC cell / PD1 inhibition of CD8+ T cells
TARC, CCL5, CCL20, CCL22,
galectin1
CD4+ TReg cell expansion of CD4+ TReg cell which
will inhibit CD8+ TC cells through
IL10 secretion
BCMA, TRKA Granulocyte / APRIL TRKA stimulation through secretion
of NGF
TARC, CCL5, CCL22, CD54,
CD40, MHCII, CD80
CD4+ TH cell / CD18,
CD11A, CD40L, TCR, CD28
promotion of TH to TReg differentia-
tion [41]
Table 1.1: cHL cellular interactions with other immune system cell types - generation of
the cHL microenvironment
TC , cytotoxic T cell; TH , T helper cell; TReg, regulatory T cell; TGFβ, transforming growth factor-β;
TNFα, tumor necrosis factor-α. Adapted from [31].
Deregulated transcription factor networks in cHL
Normally, B cell lymphomas and leukemias maintain a substantial part of their B cell
phenotype and expression pattern. In opposite, HRS cells show a nearly complete loss
of the B cell–specific expression program (see above and [42]). Most of the remaining
B cell specific factors they express are associated with antigen-presenting functions and
T helper cell communication (MHCII, CD40 and CD80) [43, 44]. Generally, HRS cells
have a very unspecific expression pattern. Markers of various hematopoetic lineages
are expressed (CD3, CD4, CD40, granzyme B, CCL17, CSF1R) and many years had
to pass before Hodgkin researchers began to understand how this is achieved [31, 45,
46]. A very significant factor towards understanding the pathogenesis of cHL is the
broad deregulation of various transcription factor networks which contributes to the
reprogramming of the former B cell specific gene expression program [27]. The list of
these transcription factor networks is still growing and in context of this work, only a
few will be mentioned (the interested reader may want to refer to Küppers et al. [31]
for a thorough and broad description).
Besides the deregulation of the NF-κB transcription factor network (see table 1.2 be-
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low), early B cell factor 1 (EBF1) is a B cell lineage transcription factor, that suppresses
the expression of myeloid and T cell genes [47] and at the same time activates the tran-
scription of B cell specific genes. As such, EBF1 is an important B-lineage commitment
factor and its expression levels in cHL are vastly reduced in comparison to normal B cells
[48]. It is thus commonly assumed, that EBF1 is one of the factors, that contributes to
the cHL specific loss of the B cell phenotype [49].
Another very important B cell transcription factor is the gene E2A which codes for
the two transcription factor proteins E12 and E47. Even though these proteins are de-
tectable in cHL, they can not function properly, as in cHL various mechanisms have
been elucidated, that impair E2A dependent transcriptional activation [48, 26, 50]. The
high level expression of the inhibitor of DNA binding 2 (ID2) is one of these mecha-
nisms. ID2 lacks a DNA binding domain, yet is able to dimerize with E2A proteins
to a form a dimer, which is not capable of transcriptional activation. ID2 is normally
expressed in dendritic cells and natural killer cells rather than in B cells and a number
of studies have provided data, indicating that this factor effectively inhibits B cell gen-
eration [51, 52]. A second mechanism to inhibit E2A mediated transcription of B cell
genes in cHL is the high level expression of activated B cell factor 1 (ABF1). ABF1 is
a transcriptional repressor capable of forming heterodimers with E2A. These dimers are
then transcriptionally inactive which will result in the down-regulation of E2A mediated
transcriptional activation [48].
The effects of down-regulation of a number of other B cell transcription factors such
as PU.1 [53] and OCT2 [54] and the up–regulation of T cell associated genes such as
NOTCH1 and NOTCH2 [55, 56] stresses the great variety of transcription factor dereg-
ulation in cHL. Last but not least, recent publications indicate, that epigenetic silencing
of B cell genes (e.g. CD19) and B cell atypical epigenetic modifications result in up–
regulation of B cell inappropriate genes such as ID2 and CSF1R [46, 57] in cHL.
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Gene Type of alteration Pathway Frequency of cases
with alterations(%)
REL Gains, amplifications NF-κB 50
NFKBIA Point mutations, deletions NF-κB 20
NFKBIE Point mutations, deletions NF-κB 15
TNFAIP3 Point mutations, deletions NF-κB 40
BCL3 Gains, translocations NF-κB 10
JAK2 Gains, amplifications Jak-Stat 40
SOCS1 Point mutations, deletions Jak-Stat 45
TP53 Point mutations, deletions p53 10
MDM2 Gains p53 60
CD95 Point mutations FAS-mediated apoptosis 10
Table 1.2: Genetic lesions in cHL
In cHL, various major pathways involved in cellular decision-making processes have been identified to
be deregulated. Often, genetic lesions play a pivotal role in their deregulation, however, as they never
occur in 100% of cHL cases are just one of many important factors to consider. The table was
adapted from [31].
Genetic lesions in cHL
In cHL, several major cellular pathways recurrently show genetic aberrations. Table 1.2
shows a short summary of those pathways and the pathway members, which have been
shown to be prone to genetic lesions in cHL cases.
In case of NF-κB signaling, a whole set of different events has been identified over
the past decades, all of which will lead to aberrantly activated NF-κB signaling . The
same is the case for members of the Janus kinase–signal transducer and activator of
transcription (Jak–Stat) signaling cascades. On the other hand, mutations of TP53 in
cHL result in inhibition of TP53 induced apoptosis [58, 59, 60].
In summary, genetic lesions add to the pathologic deregulation of various transcription
factor networks in cHL — taken together they are probably the major mechanisms
contributing to cHL pathogenesis [31].
Role of Epstein Barr Virus (EBV) infection in cHL
Various cHL studies suggest that EBV infection may play a pivotal role in causing the
onset of the disease: 40% of all cHL cases in Europe and the USA are EBV positive
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and in developing countries even 90% of all cases show to be EBV positive [61, 62, 63].
Moreover, a number of population based studies propose a statistically significant re-
lation of an EBV infection followed by infectious mononucleosis with the onset of cHL
[64, 65, 66]. Although different mechanisms have been revealed, that show how EBV
encoded proteins contribute to the pathogenetic mechanisms of cHL, the significance
of their role is still not completely understood [31] — when comparing EBV positive
cases to EBV negative cases, the EBV associated expression pattern is quite restricted
and some essential pathogenic mechanisms — for example deregulated NF-κB activ-
ity — in terms of magnitude show no significant difference in between EBV positive
and EBV negative cHL cases (though mechanistically there presumably is a difference
in deregulation of NF-κB activity, as in EBV negative cases frequent mutations of the
inhibitor of NF-κB activity, NFKBIA were detected, which are not found in EBV pos-
itive cases [67]). On the other hand EBV encoded proteins can replace pathogenetic
mechanisms found in EBV negative cHL cases [68, 69, 70, 71]. Additionally, one EBV
protein called latent membrane proteine 2A (LMP2A) migth play a pivotal role in EBV
positive cHL pathogenesis — gene expression of B cells from LMP2A transgenic mice
and ectopic LMP2A expression in human B cell lines resulted in alterations of gene
expression similar to those found in HRS cells [72]. Recently, it was also shown, that
LMP2A may constitutively activate the NOTCH1 pathway to autoregulate the LMP2A
promoter and takes advantage of the NOTCH1 signaling system to alter levels of B cell
specific transcription factors such as E2A and EBF [73].
1.1.5 Is NOTCH signaling deregulated in cHL?
Apart from playing a putative role in EBV associated cHL as mentioned above, data
from other studies indicate that the NOTCH signaling pathway itself may be deregulated
in cHL. NOTCH1 [56, 74] and NOTCH2 [56, 55] have been shown to be expressed in
10
1 Introduction
HRS cells and it is assumed, that these receptors may be activated through cells in the
microenvironment of the tumor, that express according NOTCH receptor ligands [31].
So far, no study provided in vivo evidence, that activation of the NOTCH signaling
pathway indeed is mediated through the microenvironment. This hypothesis is thus still
an assumption needing further clarification. However, a number of in vitro studies show
that:
• ectopic stimulation of the HRS cell lines with JAG1 expressing HtTA-jag10 cells
results in accelerated proliferation of HRS cells and up–regulation of the NOTCH
target gene HES1 [56]
• knockdown of NOTCH1 using siRNA results in the regulation of B lineage genes
formerly lost / down-regulated in HRS cell lines (up-regulation of e.g. EBF1, E2A
and CD79a, down-regulation of ABF1 [74] and GATA3 [75])
• JAG1 mRNA is expressed in primary cHL cases [56]
• L428 HRS cells transduced with a tamoxifen-inducable NOTCH1 intracellular do-
main (NIC1) viral construct show growth inhibition [76]
Whereas these data give some indication that NOTCH signaling may be deregulated in
a manner advantageous for cHL (though this is contradicted by the findings of Zweidler-
McKay et al. [76] mentioned above), numerous points of this particular pathway and
according questions had still to be answered:
• Is the NOTCH signaling system deregulated in a global and systemic manner in
cHL, i.e. is there a cHL specific NOTCH signature — if yes, why and how is it
deregulated?
• If a cHL NOTCH signature exists, is it dominated by a limited number of factors?
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• What is the status of all genes associated with NOTCH signaling in cHL – is a
significant number of them deregulated in any manner?
• Is the NOTCH signaling system possibly activated in a cell-autonomous manner
in cHL?
• Are there cHL specific NOTCH target genes?
In the following part, an introduction on NOTCH signaling is provided as to give an
overview on the complexity of this pathway. It shall also enable the reader to judge its
possible impact on cHL pathogenesis.
1.2 Introduction to NOTCH signaling
The NOTCH signaling pathway is one of the most conserved and essential ones for a
large number of cellular decision processes made in cellular differentiation and cell-cell
communication [77]. This pathway was named after a X-linked, dominant Drosophila
mutation, first found around 1916 by Mohr, Morgan and Bridges [78]. These mutants
exhibited irregular notches of missing tissue at their wing blades. In 1940, Poulson
found, that a complete loss of NOTCH gene activity caused lethal hyperplasia of the
embryonic nervous system, indicating that this pathway plays a pivotal role in cellular
differentiation [79].
In context of the hematopoetic compartment, NOTCH is involved in many processes
as for example stem cell development [80, 81, 82, 83, 84], T cell differentiation [85, 86, 87,
88], marginal zone B cell development [89, 90, 91, 92] and various malignancies (see also
section 1.2.2). The last decades have brought forward much data on NOTCH signaling
in Mammalia and NOTCH signaling is much better understood nowadays. Yet, the
growing number of players involved build up a very complex signaling network in which
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it is quite difficult to link a specific input to a specific output as this is largely determined
by a vast number of parameters and their concentration-, activity- and time-dynamics.
1.2.1 Core components of the NOTCH signaling cascade
In Mammalia, there are four types of proteins that compose the core components of the
NOTCH signaling pathway:
• the NOTCH receptors NOTCH1, NOTCH2, NOTCH3, NOTCH4
• the co-activators of the Mastermind-like family (MAML1, MAML2, MAML3)
• the canonical NOTCH ligands, JAG1, JAG2, DLL1, DLL3 and DLL4
• the transcription factor CSL
The NOTCH receptors
In Mammalia, 4 NOTCH receptors have been identified so far. They are single-pass
transmembrane proteins. The extracellular domain of either receptor protein is com-
posed of 29-36 epidermal growth factor (EGF) repeats, of which especially EGF repeats
number 11 and 12 are important for ligand binding [93]. The EGF repeats are followed
by three cystein-rich LIN domains which prevent ligand independent activation, and the
heterodimerization domain (HD). The NOTCH intracellular domain (NIC) possesses
one to two nuclear localization signals and is composed of a RAM domain followed
by six ankyrin repeats. These are important for binding to the transcription factor
CSL. Finally, the cytoplasmatic domain contains — in case of NOTCH1 and NOTCH2
— a transactivation domain and all receptors possess a PEST domain important for
proteasome-mediated degradation [77].
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The Mastermind-like family of NOTCH co-activators
The first member of the human Mastermind-like family, MAML1, was identified by Wu
et al. in 2000 [94], the other two known members, MAML2 and MAML3, were first
described in 2002 independently by two groups [95, 96]. These proteins are human ho-
mologues of Drosophila Mastermind. The family members share high amino acid identity
among each other, compared to MAML1, MAML2 has 45% and MAML3 has 34% iden-
tical amino acids [96]. All human MAML proteins share the same domain structure
which is composed of a N-terminal binding domain (mediating binding to NIC and the
transcription factor CSL) followed by two transactivation domains. MAML proteins are
essential for the formation of a transcriptionally active NOTCH transcriptional complex
(NTC) [97]. They activate NOTCH signaling with different potentials. As shown in
[95], MAML2 has the highest potential to activate the NTC mediated transcription of
the NOTCH target gene HES1. At the same time MAML proteins may also play a role
in the degradation of the NTC, as MAML1 has been shown to recruit CDK8 which in
turn phosphorylates NIC and thereby may coordinate NTC turnover [98]. In how far
different MAML members may contribute to fine-tuning of NOTCH signaling is still at
large, yet a recent study provides evidence, that the potential of MAML proteins to
activate NOTCH signaling in general is in turn modified through SUMOilation [99].
In terms of their biological functions, recent studies have brought forward much data,
indicating that MAML proteins are especially important and essential for lymphoid cell
fate decisions [100, 101, 92]. Interestingly, MAML proteins are also involved in various
other signaling pathways such as NF-κB and p53 (see for example [102, 103]) and — in
case of MAML2 — have been shown to be a potent oncogenic inducer when aberrantly
fused to TORC1 or MECTC1 by translocation [104, 105].
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Canonical NOTCH ligands
The five conventional NOTCH ligands all contain EGF repeat domains and an amino-
terminal domain called DSL (Delta, Serrate, and Lag-2). This domain is highly con-
served among species and involved in NOTCH receptor binding. In case of JAG1 and
JAG2 there is an additional cystein rich domain adjacent to the plasma membrane. In
terms of functionality, one study indicates, that JAG1 expression is essential for the
generation of hematopoietic cells in the aorta-gonad mesonephros [106]. This study also
linked JAG1 expression to NOTCH1 mediated expression of the transcription factors
GATA2 and RUNX1. JAG2, DLL1 and DLL4 have also been shown to be important
in the process of differentiation of CD34+ cord blood hematopoetic progenitor cells to
Natural killer cells [107].
The transcription factor CSL
CSL (CBF1, Su(H) and LAG-1) is the key transducer of the NOTCH signaling pathway.
It is a transcription factor sharing similarity with the Rel family of transcription factors,
yet differs from Rel in that it contains a β-trefoil domain in between two Rel-homology
domains. The β-trefoil domain contains a hydrophobic pocket that probably mediates
interaction with NIC [93]. So far, four splice variants of CSL have been deposited in
public databases (see e.g. http://www.ncbi.nlm.nih.gov/gene/).
NOTCH — from translation to activation
In canonical NOTCH signaling, each combination of one of each of the four protein-types
described above comprises the essential components for the assembly of a transcription-
ally active NTC – all other proteins necessary for transcriptional activation belong to the
basic transcription machinery of a cell (e.g. CREBBP and EP300) and are not specific
for the NOTCH transcriptional activation. After translation of the NOTCH receptors
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the ≈300 kDa sized proteins are cleaved by furin-like convertases [108] (S1-cleavage)
into two parts which are then re-assembled as a heterodimer. This heterodimer then
translocates to the cellular membrane. Upon receptor-ligand interaction, the next —
S2-cleavage called — step is mediated by ADAM metalloproteases and results in trun-
cation of the extracellular domain of the NOTCH receptor (called NOTCHTM). At that
time, the receptor is still membrane-bound yet accessible for the final S3-cleavage step.
This step is mediated by the γ-secretase complex and will result in the release of the
NOTCH intracellular domain (NIC). NIC shuttles to the nucleus where it binds to CSL
(an otherwise repressive transcription factor that is quasi-statically bound to DNA in
complex with various co-repressors such as NCOR2). Thereby a dual binding interface
is formed, to which Mastermind-like family members may bind. This complex consisting
of DNA/CSL/NIC/MAML is the essential NTC-assembly necessary for transcriptional
activation. Figure 1.3 shows, how the S2 and S3 cleavage steps of a NOTCH receptor
will result in the cell-contact mediated activation of the pathway.
NOTCH transcriptional activation — adding to the complexity
A vast number of proteins and processes influence NTC dependent transcription. For
example, the presence, number and spatial orientation of CSL binding sites has a major
impact on the magnitude of the transcriptional read-out mediated by NOTCH signaling
[111]. Additionally, it is not yet understood, in how far ligand-receptor interactions
are integrated to an intracellular message. This is a complex, concentration dependent
process, that recently has been mathematically modeled for DLL1-NOTCH1 mediated
NTC activation [112].
Apart from that, many other mechanisms influence NOTCH activation at other parts
of the signaling cascade. For example the ubiquitylation status of ligands which is de-
termined by E3 ubiquitin ligases such as NEURL and MIB1 plays an important role
[113, 114, 115, 116, 117] as does the glycosylation status of the NOTCH receptors (de-
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Figure 1.3: Activation of NOTCH signaling
Shown is a simplified scheme of NOTCH transcriptional activation. Note, that various other molecules
such as glycosyl transferases and ring finger E3 ligases play important roles in tuning the NOTCH
activation potential. For a thorough description of these proteins in regard to NOTCH signaling
please refer to [93]. However, this scheme shows all proteins and steps that are absolutely essential for
NOTCH transcriptional activation.
When NOTCH signaling is not activated, the repressive transcription factor CSL is bound to DNA
and recruits various co-repressors (CoR). In this state, no transcription is possible from CSL-binding
sites. As soon as the NOTCH receptors are translated, a first cleavage step (S1, not shown) will result
in the production of two parts of the receptor. This step is done by furin-like convertases and takes
place in the trans-Golgi compartment [108]. The NOTCH extracellular domain (NE) and the NOTCH
intracellular domain (NIC) are assembled to form a singlepass, transmembrane recptor. Upon ligand
binding, ADAM proteases will mediate S2 cleavage (resulting in the cleavage product NOTCHTM ),
which is then followed by γ-secretase complex-mediated S3 cleavage. This results in the release of NIC
which may then translocate to the nucleus (NIC possesses nuclear localization sequences [109, 110]).
There it displaces the CoRs, binds to CSL, thereby forming a dual binding-interface for binding of the
co-activators of the Mastermind-like family (MAML). Binding of MAML proteins occurs via their
binding domain (BD), whereas their transcriptional activation is mediated through two
trans-activation domains (TADs). The now formed complex can then recruit standard proteins
involved in transcription (e.g. EP300) and will activate transcription from CSL binding sites. Note,
that the magnitude of transcriptional activation also depends on the number and spatial positioning
of CSL binding sites in immediate proximity to each other [111]. HD, heterodimerization domain;
PEST, proline, glutamate, serine and threonine enriched domain.
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termined by various glycosyl transferases of the fringe family, such as LFNG and MFNG
[118, 119, 120, 121, 122]) and their ubiquitination (modified by the protein NUMB
[123], which thereby inhibits NOTCH signaling). Moreover a recent study indicates
that Nemo-like kinase physically modulates NOTCH signaling by interfering with the
formation of the NOTCH transcriptional complex [124].
In turn all these NTC modifying molecules are regulated themselves, making it obvious
that complete understanding of the complexity of the regulation of NOTCH signaling
and the prediction of its dynamics are still far away.
1.2.2 Pathological deregulation of the NOTCH signaling pathway
Due to its involvement in decisive steps of cellular life, NOTCH signaling has to be
controlled and fine-tuned in a very sophisticated and tightly controlled manner. Any
deregulation of this pathway most probably results in severe effects leading to pathogenic
events. Numerous diseases are associated with deregulated NOTCH signaling [77].
For example there are implications of pathologically deregulated NOTCH signaling in
Alagille syndrome (a developmental disorder partly caused by mutations of NOTCH2
[125]), ovarian cancer (in a significant number of cases the NOTCH3 gene is amplified
[126]), breast cancer (associated with the impaired NOTCH-inhibition mediated through
NUMB [127]) and T cell acute lymphoblastic leukemia (T-ALL) [128].
In human cancers, T-ALL is best examined in regard to the mechanisms leading
to pathologically deregulated NOTCH signaling. Two major mechanisms have been
elucidated, that are responsible for aberrant NOTCH activation as found in T-ALL:
• Mutations within the NOTCH receptor, that may lead to ligand independent, facil-
itated cleavage of the receptor. These mutations are usually found in the NOTCH
heterodimerization domain. Additionally, NOTCH mutations of the PEST do-
main are frequently found, these may impair turn-over of cleaved NOTCH and
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thus increase its half-life [129]. Both types of mutations are found in around 50%
of T-ALL cases [128].
• Mutations or deletions of ubiquitin ligases that mediate the turn over of the
NOTCH transcriptional complex — e.g. FBXW7 — this results in increased half-
life of the NTC [130].
Yet, exactly these two mechanisms diminish treatment possibilities of deregulated
NOTCH signaling with γ-secretase inhibitors (GSIs) such as compound E or DAPT.
GSIs target the NOTCH signaling cascade by inhibiting the S3 cleavage step through
a variety of mechanisms and were originally developed for the treatment of Alzheimer’s
Disease (AD) in which deregulated γ-secretase activity presumably contributes to patho-
genesis [131]. Though effective when NOTCH signaling is deregulated by for example
NOTCH gene amplification these compounds are ineffective when NOTCH deregulation
is mediated by mechanisms independent of γ-secretase mediated S3 cleavage. Never-
theless, for NOTCH-associated disease entities in which this is not the case, GSI usage
may be an option. Recent clinical trials report, that there are no severe side effects or
acute toxicities associated with treatment using GSIs [132, 133]. However, for malig-
nancies with mechanisms rendering NOTCH activation independent of S3-cleavage, new
therapeutic strategies will have to be developed.
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1.3 Aim of this work
As mentioned above, at the beginning of this study a number of very relevant questions
regarding the actual role of the NOTCH signaling system in Hodgkin lymphoma had
not been satisfyingly answered. Hence, this study aimed to determine and describe the
general and cell–biological characteristics of the NOTCH signaling system in cHL in a
holistic fashion. The major working hypothesis was summarized as follows:
If the NOTCH signaling system is pathologically deregulated in classi-
cal Hodgkin lymphoma, this must result in and/or must be the result of
the deregulation of a statistically and biologically significant number of
NOTCH associated genes.
Accordingly, one would assume, that classical Hodgkin lymphoma should
be characterized by a specific NOTCH signaling system signature, speci-
fiable by quantifying mRNA or protein levels of all NOTCH associated
genes. One would moreover assume, that experimental perturbation of the
NOTCH signaling system in cHL should result in significant cell–biological
effects.
Ergo, a holistic specification and definition of the NOTCH signaling sys-
tem is the prerequisite for the systemic understanding of its role in cHL.
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2.1 Materials
2.1.1 Antibiotics
The following antibiotics used for bacteria cultures were purchased from Sigma Aldrich
and applied at the stated concentrations:
• Ampicillin (50µg/ml)
• Kanamycin (30µg/ml)
• Tetracyclin (12.5µg/ml)
As additive in mammalian cell culture, Penicillin (10.000Units/ml) and Streptomycin
(10mg/ml) were purchased from PAA Laboratories solved in 0.9% NaCl-H2O.
2.1.2 Antibodies used for Western Blotting
Antibody Product number, Supplier
β-actin A5441, Sigma Aldrich
CD19 R0808, Dako
CD3 R0810, Dako
FLAG-tag F3165, Sigma Aldrich
GFP BA-0702, Vector Laboratories
MAML1 4608, Cell Signaling
MAML2 4618, Cell Signaling
MAML3 NB100-2129, Novus Biologicals
MYC-tag 46-0603, Invitrogen
cleaved NOTCH1 2421, Cell Signaling
NOTCH1 N6786, Sigma Aldrich
NOTCH2 clone C651.6DbHN, Developmental Studies Hybridoma Bank,
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University of Iowa
NOTCH3 34465, Cell Signaling
NOTCH4 2423, Cell Signaling
PARP1 sc-8007, Santa Cruz Biotechnology
2.1.3 Buffers
Where applicable, pH of a buffer was measured using a pH-meter.
1l ofPhosphate buffer pH 7.0 was prepared by mixing 39ml of 0.1M K42HPO4 and
61mL of 0.1M KH2PO4 and addition of 900ml H2O.
10× Phosphate buffered saline (PBS) stock solution was prepared by dissolving 80 g/l
NaCl, 2 g/l KCl, 26.8 g/l Na2HPO4-7H2O and 2.4 g/l KH2PO4 in double distilled H2O.
The pH was adjusted to 7.4 by adding HCl. Buffer was autoclaved before usage.
10×Tris Borat EDTA (TBE) stock solution were prepared by dissolving 108 g/l Tris,
55 g/l Boric acid in H2O and addition of 40ml/l Na2EDTA pH 8.0.
1M Tris-HCL stock solution was prepared by dissolving 121.14 g/l Tris in double distilled
H2O. The desired pH was adjusted by adding concentrated HCl. Buffer was autoclaved
before usage.
High Salt Lysis (HSL) buffer : 20mM HEPES pH 7.9, 350mM NaCl,1mM MgCl2,
0.5mM EDTA pH 8.0, 0.1mM EGTA pH 7.6, 1% (v/v) Nonidet P-40. A protease
inhibitor cocktail was added just before usage: 1 pill/10ml HSL buffer Complete, Mini
Protease Inhibitor Cocktail and NaF and Na3VO4 to final concentrations of 1mM each.
Buffers for extraction of nuclear proteins:
• Buffer A: 10mM HEPES pH 7.9, 10mM KCl, 0.1mM EDTA pH 8.0, 0.1mM
EGTA pH 7.6, 1mM DTT. A protease inhibitor cocktail was added just before
usage: 1 pill/10ml buffer Complete, Mini Protease Inhibitor Cocktail and NaF
and Na3VO4 to final concentrations of 1mM each.
• Buffer C: 20mM HEPES pH 7.9, 0.4M NaCl, 1mM EDTA pH 8.0, 1mM EGTA
pH 7.6, 1mM DTT, 20% glycerol (v/v). A protease inhibitor cocktail was added
just before usage: 1 pill/10ml buffer Complete, Mini Protease Inhibitor Cocktail
and NaF and Na3VO4 to final concentrations of 1mM each.
Shift-buffer for CSL EMSA: 40mM HEPES pH 7.9, 100mM KCl, 5mM EDTA pH 8.0,
16mM MgCl2, 10mM Spermidine, 35µg/ml Poly(dI-dC), 500µg/ml BSA, 0.05% (v/v)
Nonidet P-40, 30% glycerol (v/v), 8% Ficoll 400.000 (w/v).
SDS-PAGE sample buffer : 10% SDS (w/v), 10mM DTT, 20% glycerol (v/v), 0.2M
Tris-HCl pH 6.8, 0.05% bromphenol blue (w/v).
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SDS-PAGE running buffer : 25mM Tris-HCl pH 8.3, 200mM Glycine, 0.1% SDS (w/v).
Western blot transfer buffer : 25mM Tris, 192mM glycine, 10% MeOH.
1×TBS buffer : 150mM NaCl, 7.7mM Tris-HCl pH 7.5.
2.1.4 Chemicals
Chemical Supplier
Agarose ROTH
Acrylamide/Bis-solution 40% ROTH
CaCl2 Sigma Aldrich
bacto-tryptone ROTH
bacto-yeast ROTH
β-Mercapthoethanol ROTH
bovine serum albumin (BSA) fraction V ROTH
bromphenol blue Sigma Aldrich
DMSO ROTH
DTT ROTH
EDTA Sigma Aldrich
EtOH MDC Distillery
Ficoll PAA laboratories
Glycerol Sigma Aldrich
HCl ROTH
HEPES ROTH
Imidazol MERCK
IPTG Roche
KCl Sigma Aldrich
MeOH ROTH
Milkpowder Kaufland
Na2HPO4 Sigma Aldrich
Na3VO4 ROTH
NaCl Sigma Aldrich
NaF Sigma Aldrich
NaH2PO4 Sigma Aldrich
NaOH Sigma Aldrich
Nonidet P-40 Roche
Poly(dI-dC) acid sodium salt Roche
RbCl Sigma Aldrich
Sodium-dodecyl-sulfate ROTH
Spermidine Sigma Aldrich
TEMED ROTH
Tris Sigma Aldrich
Triton X 100 Roche
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2.1.5 Consumables
Consumable Supplier
3H-thymidine New England Biolabs
32P-dCTP New England Biolabs
4mm electroporation cuevettes Invitrogen
BCA Protein Assay Pierce
Complete, Mini; Protease Inhibitor Cocktail Roche
dNTPs Fermentas
DreamTaq™ and additives Fermentas
Falcons FalCon GmbH
HG-U133 Plus 2.0 Affymetrix
MicroBeads (CD19 and CD3) Miltenyi Biotec
MACS cell seperation columns Miltenyi Biotec
Optical 96-well plates Thermo Scientific
Power SYBR® Green Applied Biosystems
Prescission-protease GE Healthcare
Reaction tubes / tips Eppendorf
Smart Pool siRNA (MAML2 /control) Thermo Scientific
Nitrocellulose membrane Whatman
Quick Spin Columns Sephadex G50 fine Roche
2.1.6 Kits
Product Supplier
Dual-luciferase Kit Promega
First strand cDNA synthesis kit Roche
Invisorb Spin Plasmid Mini Invitek
Invisorb Plasmid Maxi Kit Invitek
Invisorb Spin Dna Extraction Invitek
RNeasy Mini Kit Qiagen
2.1.7 Machines
Machine Supplier
ABI StepOnePlus Applied Biosystems
ÄTKA-FPLC system Amersham Biosciences
ÄTKAprime fraction collector Amersham Biosciences
Beckman counter Beckman Coulter
FACSAria™III BD Biosciences
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FACSCanto™II BD Biosciences
Eppendorf Mastercycler gradient Eppendorf
Gene-Pulser II BioRad
HP xw4600 workstation HP
MicroCal VP-ITC GE Healthcare
Mithras LB940 Luminometer Berthold Detection Systems
Nanodrop ND-100 Peqlab
2.1.8 Media for bacteria culture
Lysogeny broth (LB): 10 g/l bacto-tryptone, 5 g/l bacto-yeast extract, 10 g/l NaCl.
Terrific broth (TB): 12 g/l Bacto-tryptone, 24 g/l bacto-yeast extract, 2,13 g/l KH2PO4,
12,54 g/l K2HPO4.
Media were autoclaved before usage. Appropriate antibiotics were added after autoclav-
ing.
2.1.9 Media for eukaryotic cell culture
Product Supplier
RPMI1640 Invitrogen
Opti-MEM® I Invitrogen
GlutaMAX® Invitrogen
2.1.10 Software
Software Supplier
Bioconductor 2.5 http://www.bioconductor.org
Canvas X AOD Systems
EndNote X2 Thomson Cooperation
JAVA GSEA implementation http://www.broadinstitute.org/gsea/
MiKTeX 2.8 http://miktex.org/
R 2.10 www.r-project.org
SigmaPlot 9.0 SysStat Software Inc
UCSF Chimera 1.4.1 http://www.cgl.ucsf.edu/chimera/
2.1.11 Used vector-backbones
Product Supplier
pEGFP-N3 Clontech
pcDNA3.1(+) Invitrogen
pcDNA3.1/V5-His Invitrogen
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pGL2 Promega
pGEM-TEasy Promega
pCMV-Myc Clontech
pSuper Brummelkamp et al.
pSKB2LNB Daumke et al.
2.2 Methods
2.2.1 Cell lines and culture conditions
cHL (L428, L1236, KM-H2, L591, HDLM-2, L540, L540Cy), pro-B lymphoblastic leu-
kemia (Reh), Burkitt’s lymphoma (Namalwa, BL-60, BJAB), diffuse large B-cell lym-
phoma (DLBCL, SU-DHL-4), T lymphoblastic lymphoma (SUP-T1), T cell acute lym-
phoblastic leukemia (ALL-SIL) and HEK293 cells were cultured at 37°C, 5% CO2
in RPMI1640 supplemented with Penicillin (100Units/ml), Streptomycin (0.1mg/ml),
sodium pyruvate (0.11 g/l) and L-Glutamine (2mM).
2.2.2 Electrophoretic Mobility Shift Assay (EMSA) for NTC
assembly monitoring
CSL EMSA was performed using the high-affinity CSL binding site (described previously
[134]) from the HES1 promoter using the following oligonucleotides (overhang for labeling
in small letters, binding sequence in capitals):
sense 5’-gatcCTAGGTTACTGTGGGAAAGAAAGTCC-3’
antisense 5’-gatcGGACTTTCTTTCCCACAGTAACCTAG-3’
As for the shift buffer, see section 2.1.3 for the complete buffer composition. 0.33µg/µl of
each oligonucleotide were dissolved in annealing buffer (10×-annealing buffer: 500mM
TRIS-HCL pH 8.0, 700mM NaCl in H2O) and then annealed by incubating the mixture
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at 95°C for 20min and slow cooling down to room temperature. Labeling of the an-
nealed oligonucleotides was done with 32P-dCTP, a final oligonucleotide concentration
of 10 ng/µl, Klenow enzyme (6U), a final concentration of 360 nM of each dATP, dGTP
and dTTP and the appropriate Klenow-buffer. The labeling mixture was incubated at
37°C for 30min and then purified using Quick Spin Columns Sephadex G50 fine for
radiolabeled DNA Purification. EMSAs were performed with 5µg of nuclear extracts
on non-denaturing, 5% polyacrylamide gels using 1×TBE pH 8.3 as buffer.
For preparation of nuclear extracts for CSL EMSAs, HEK293 were transfected with
different combinations of 10µg Myc-tagged CSL, 10µg Flag-tagged ICN1, 20µg
MAML1, 40µg DnMAML1-pEGFP AA 13-74, 40µg DnMAML1-pEGFP AA 13-50,
70µg of DnMAML1-pEGFP AA 19-35, and total DNA amount was adjusted with empty
plasmid. Cells were harvested after 48 hours.
2.2.3 Generation of plasmids and DNA constructs
MAML1 and MYC-CSL constructs were described before [95]. MAML2 was mobilized
from the previously described MAML2-pEFBOS construct [96] by digestion with NotI
and XhoI and cloned into pcDNA3.1(+). The DnMAML1-pEGFP amino acids (AA)
13-74 and the ICN1-pcDNA3.1 expression constructs as well as the Hes1-pGL2 reporter
construct were described previously [135]. The truncated versions DnMAML1 AA 13-50
and AA 19-35 were cloned into pEGFP via HindIII and KpnI restriction sites using
HPLC grade oligonucleotides. Sequences for the shMAML2 constructs were selected
based on siRNA sequences from the Dharmacon MAML2 ON-TARGETplus SMARTpool
(L-013568-00, Dharmacon, Lafayette, CO). To generate shRNA expression constructs,
the sequences (targeting sequence in bold, backbone sequence in normal)
• 5’-GATCCCCGGACAAAGTCAGATTATGTTTCAAGAGAACATAATCTGACTTTGTCCTTTTTGGAAA-3’
• 5’-GATCCCCCGAAAGTAATGGCTAACTATTCAAGAGATAGTTAGCCATTACTTTCGTTTTTGGAAA-3’
• 5’-GATCCCCAGACCAAATTTAACCCATATTCAAGAGATATGGGTTAAATTTGGTCTTTTTTGGAAA-3’
27
2 Materials and Methods
were cloned via BglII and HindIII restriction sites into pSUPER using HPLC grade
oligonucleotides. The scrambled shRNA construct has been previously described [136].
All constructs were verified by sequencing.
2.2.4 Immunohistochemistry (IHC)
IHC was kindly done by Prof. Dr. Anagnostopoulos and Dr. Jöhrens from the Institute
of Pathology, Charité, Berlin. All cases were drawn from the files of the Consultation
and Reference Center for Hematopathology at the Institute of Pathology, Campus Ben-
jamin Franklin, Medical University Berlin. Diagnoses were established according to the
WHO criteria. The primary antibody used was anti-MAML2 (see section 2.1.2). Bound
antibodies were made visible using the streptavidin-biotin-alkaline phosphatase method
and FastRed as chromogen (all from DakoCytomation, Glostrup, Denmark).
2.2.5 Isothermal Titration Calorimetry (ITC)
ITC measurements of concentration-dependent compound-protein binding were per-
formed on a VP–ITC instrument from MicroCal. The injection syringe (500µl volume)
was loaded with a 100µM solution of either compound. The calorimetry cell was loaded
with purified human CSL at a concentration of 2mg/ml in 20mM phosphate buffer sup-
plemented with a final concentration of 1mM of BME. The protein solution was degassed
before usage. After equilibration at the desired temperature, a series of 21 injections of
10µl of the compound solution were done and the heat response was measured by the
instrument using a power-compensation mechanism.
2.2.6 Isolation of primary lymphocytes
Primary CD19+ B cells and CD3+ T cells were isolated from human tonsils with CD19 or
CD3 MicroBeads according to the manufacturer’s recommendations. Purity of CD19+
28
2 Materials and Methods
B and CD3+ T cells was greater than 95%, as determined by staining of purified cells
with CD19- and CD3-specific antibodies and subsequent FACS analysis.
The use of human material was approved by the local ethics committee of the Charité,
and performed in accordance with the Declaration of Helsinki.
2.2.7 MAML2 knockdown and DnMAML1 based NOTCH
inhibition experiments
Cells were transfected with 60µg DnMAML1-pEGFP AA 13-74 fusion construct or 60µg
of pEGFP control plasmid, or with each 20µg of three different shMAML2-pSuper based
expression constructs or 60µg of scrambled shRNA construct as control, both along
with 10µg of pEGFP. 48 hours after transfection, GFP+ cells were enriched by FACS
sorting and enriched cells were used for proliferation assays as well as RNA and protein
extraction.
2.2.8 Preparation of whole-cell and nuclear extracts, SDS-PAGE
and Western Blotting (WB)
Whole-cell extracts were prepared as follows:
1. cells were taken from culture flasks, centrifuged 5min at 1200×g, RT, supernatant
was decanted
2. cells were resuspended in PBS, centrifuged 5min at 1200×g, RT, supernatant was
decanted
3. cells were resuspended in an appropriate volume of HSL buffer and put on ice for
15min
4. cell-suspension was centrifuged 5min at 1200×g, 4°C, supernatant was transferred
to a new reaction tube, protein concentration was determined using a standard
BCA protein assay by measuring light absorption of the BCA-protein solution at
595 nm
5. proteins were put on liquid nitrogen and then stored at -80°C until usage
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Nuclear extracts were prepared as follows:
1. cells were taken from culture flasks, centrifuged 5min at 1200×g, RT, supernatant
was decanted
2. cells were resuspended in PBS, centrifuged 5min at 1200×g, RT, supernatant was
decanted
3. cells were resuspended in an appropriate volume of nuclear buffer A and put on
ice for 15min
4. Nonidet P-40 was added to a final concentration of 1% (v/v) and cell suspesion
was vortexted vigorously for 15 sec
5. cells centrifuged 5min at 1200×g, 4°C, supernatant was decanted
6. nuclear pellets were resuspended in nuclear buffer C and put on ice for 15min
7. nuclear pellet-suspension was centrifuged 5min at 1200×g, 4°C, supernatant was
transferred to a new reaction tube, protein concentration was determined using
a standard BCA protein assay by measuring light absorption of the BCA-protein
solution at 595 nm
8. proteins were put on liquid nitrogen and then stored at -80°C until usage
SDS-PAGE : For SDS-PAGE separation of proteins, polyacrylamide concentrations were
used according to the size of the protein of interest, in case of MAML and NOTCH
proteins the concentration was 7.5%. SDS-PAGE gels were put into the appropriate
chamber and filled with SDS-PAGE running buffer. Protein samples were incubated
at 95°C for 5min prior to application on the SDS-PAGE gel. SDS-PAGE were run at
80-120V.
Western blot analyses: SDS-PAGE gels were transferred to a nitrocellulose membrane
and then put into the appropriate blotting chamber which was filled with WB transfer
buffer. For large proteins like MAML and NOTCH members, wet-blotting was used
(100V at 4°C for 2 hours), for smaller proteins semi-dry blotting was used instead (20V
at RT for 45min). Western blots were developed using 1× TBS buffer supplemented
with 10 g/l skim milk powder and 0.1% Triton X-100 (v/v).
30
2 Materials and Methods
2.2.9 Proliferation assays
24 hours before proliferation assay set up, cells were diluted to ≈ 100000-400000 cells/ml.
At the day of assay set up, cells were diluted to 50000 cells/ml and 200µl of cell suspen-
sion were put into the wells of a 96 well plate (each sample was pipetted and measured in
quadruplicates). 24 hours before the desired time of measurement each cell-containing
well was pulsed with [3-H]-thymidine to a final concentration of 1µCi/ml. Cells were
harvested and [3-H]-thymidine incorporation measured 24 hours after pulsing.
2.2.10 Reporter assays
For measurement of luciferase activity, HEK293 and SUP-T1 cells were transfected
with 10µg of the Hes1-pGL2 promotor construct and 100 ng pRL-TKLuc as an in-
ternal control. Where indicated, cells were cotransfected with 5µg Flag-tagged ICN1,
30µg (HEK293) or 60µg (SUP-T1) MAML2 expression constructs or both. Equal DNA
loads were achieved by adding according amounts of empty plasmid. For assaying the
functional activity of MAML1-based peptide-pEGFP constructs, SUP-T1 cells were co–
transfected with 80µg of either pEGFP, or the various DnMAML1-pEGFP constructs,
as indicated, along with 10µg of the Hes1-pGL2 promotor construct and 100 ng pRL-
TKLuc as an internal control. 48 hours after transfection, cells were lysed and the ratio
of the two luciferases was determined.
2.2.11 RNA preparation, semi-quantitative (sqPCR)and
quantitative PCR (qPCR) analyses
Total RNA was extracted from cells using the Qiagen RNeasy Mini Kit according to
the manufacturer’s recommendations. Upon completion of the process, RNA was shock-
frozen in liquid Nitrogen. cDNA first strand synthesis was performed using the Roche
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1st Strand cDNA Synthesis Kit according to the manufacturer’s recommendations using
oligo-dT primers and 1µg of total RNA, whenever there was no amount-limitation. If
there was an amount-limitation, total RNA amounts used were adjusted to the sample
with the lowest RNA concentration.
Primer sequences used in sqPCR and qPCR are listed in table 2.1. sqPCR were per-
formed as standard two-step program (annealing and elongation in two different tem-
perature steps). qPCR analyses were performed using Power SYBR® Green Mastermix
and the ABI StepOnePlus real-time PCR system in a one-step procedure (annealing and
elongation at one temperature). Relative quantities were calculated using the 2−∆∆Ct
method taking into account the according primer efficiencies. For primer efficiency de-
termination, CT values for five different cDNA concentrations were measured and then
fitted according to the simple linear model:
CTi = ai + xi × log10 c + i
where ai is the y-intercept of the model for primer pair i, xi the slope-estimator, c the
concentration and i the error of the model for each primer pair i. The efficiency E was
then calculated from the slope-estimator:
E = −1 + 10−1/xi
All PCR products were verified by sequencing.
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Table 2.1: Primers used for sq- and qPCR
Name PCR type Forward primer (5’-3’) Reverse primer (5’-3’) Product size (bp)
CSL sq GTTGAATGGCGGTGGGGACGT CAGCACTTGCAGGGAGACAACGG 575
GAPDH sq ATGCTGGCGCTGAGTAC TGAGTCCTTCCACGATAC 257
MAML1 sq CGAGCAGAACTCCCTGTTTC CCCTGTGAACTGTCCAACCT 414
MAML2 sq TGCAGGAATGGGATACCAAG TGCCAAAGCCTGGTTAGAGT 399
MAML3 sq CCTGAGCGAAGACCAGAAAC TGGCTTCTTACGGCTGCTAT 461
HEY1 sq TCATTTGGAGTGTTGGTGGA CCAGTTCAGTGGAGGTCGTT 399
HES7 sq GCGGGTGAGATGTGGTCTAT GTTCGAATCCCACCAGAGTC 451
GAPDH q CTCTGCTCCTCCTGTTCGAC TTAAAAGCAGCCCTGGTGAC 144
HES7 q TACTCTCTCTGCCCCTCAGC GACGTCGAGATAAAGGCAGG 119
HEY1 q CGAGGTGGAGAAGGAGAGTG TCGGCGCTTCTCAATTATTC 127
MAML1 q CACTCCCATGTCAGATGACTTGCAC GGGTCTCACCCTGTGCTTACCA 198
MAML2 q ACATTTGTCAAGGCCACCTC GTTTGCCAAAGCCTGGTTAG 125
MAML3 q AAGCCCAGGGACCGAGGCAA GCAGCCTTGGAGGGGCTTGG 160
NOTCH1 q CCAGCTCGTCCCCGCATTCC GCGCGCCGTTTACTTGAAGGC 115
NOTCH2 q GGGGACCCTGTCATACCCTCTTGTG TCCCACTGGCTCACGACGCT 225
NOTCH3 q ABI Taqman # Hs01128541_m1 ABI Taqman # Hs01128541_m1 81
NOTCH4 q TCCGTAGCAGACAAACTGCAGTGG CTTTATCGGCTCCGGCCTGGAG 221
JAG1 q CAATAGGATGGGCTTCTGTGCCCAG TGCAGCAGATCACCTGCCTGTCT 209
JAG2 q TGAGTGTGAAGGGAAGCCATGCC TGCCCGCGACAGTCGTTGAC 128
DLL1 q TCGTCAACAAGAAGGGGCTGCTG TCGGGCAGACTGAAGGAGTCGAC 192
DLL3 q CCGACTCCGCCAGAGCTTTTCC GCAGAGACTGGGCACCACCGA 176
DLL4 q GTCTCCACGCCGGTATTGGGC CCGGTAAGAGTAGCGCAGCCTTG 281
sq, semi-quantative; q, quantitative
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2.2.12 Size exclusion chromatography (SEC)
SEC was performed using 20mM phosphate buffer pH 7.0 with a Sephadex G-200 column
and the ÄKTA-FPLC system with an ÄKTAprime fraction collector. Buffers were
filtered and degassed before usage.
2.2.13 Statistical analyses of experimental and microarray data
All statistical analyses were done in R v2.9.1 (http://www.r-project.org/)[137]). Inde-
pendent Student’s t-test was used to analyze data from proliferation- or real-time PCR-
experiments. For analyses of luciferase assays, one way analysis of variance (ANOVA)
was done before applying Tukey’s Honestly Significant Differences test with 95% family-
wise confidence level.
For microarray analysis of the various cell lines, RNA processing and hybridization
to Affymetrix Human Genome U133 Plus 2.0 arrays were performed according to the
manufacturer’s recommendation. Raw microarray data was processed using the Biocon-
ductor v2.4 framework [138]. RMA background correction and quantile normalization
were applied. The LIMMA package was used for fitting gene-wise linear models and to
calculate moderate t- and F-statistics for determination of significantly differentially ex-
pressed genes [139]. Fisher’s Exact test was used for testing significance of deregulation
of the NOTCH gene set. Unrotated principal component (PC) analysis was applied for
analysis of intensity values of NOTCH associated genes. Gene set enrichment analysis
(GSEA) was done as described in [140], ranking array-features according to their signal
to noise ratio defined by:
ratioi =
µA − µB
σ2A + σ2B
where µi is the average intensity of anyone feature in the biological groups and σ2i the
standard deviation of the intensity of anyone feature in the according biological group.
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Microarray data are available through Gene Expression Omnibus accession number
GSE20011.
2.2.14 Transfection of mammalian cells
24 hours before transfection, cells were diluted to ≈ 100000-400000 cells/ml. Cells were
electroporated in OPTI-MEM I using a Gene-Pulser II with 950µF and 0.18 kV (L428,
HEK293), 500µF and 0.3 kV (L591), 500µF and 0.28 kV (SUP-T1), 50µF and 0.5 kV
(BJAB). Transfection efficiency was determined by pEGFP cotransfection and FACS
analysis or by FACS analysis of pEGFP-fusion constructs, where used.
35
3 Results
3.1 Part I: High-dimensional data as basis for
identification of a cHL-NOTCH disease mechanism
3.1.1 Defining a NOTCH gene set
Publicly available NOTCH gene sets (http://www.broadinstitute.org/gsea/msigdb) were
screened and found to represent only core components of the signaling pathway in addi-
tion to some classical NOTCH target genes. Hence, these sets are incomplete in terms
of comprising every gene that has been found to be associated with NOTCH. They for
example lack various proteins that may fine tune NOTCH activation, proteins that are
known to interact physically with NOTCH receptors of whom a direct function is yet to
be shown but presumably exists (see e.g. the BioGrid database, http://thebiogrid.org/).
They moreover do not include a vast number of described NOTCH target genes such
as for example GATA3 [75], ABF1 [74] and HOXA5 [141]. To obtain a set of all genes
where there is evidence of either
• protein interaction with NOTCH receptors
• tuning of the NOTCH signaling pathway
• target gene regulation through NOTCH transcriptional activity
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the following databases where screened: BioGrid, KEGGpathway, Pubmed and NetAffx.
Appendix A lists all genes that were found to be associated with the NOTCH signaling
pathway.
To check NOTCH specificity of this set, it was analyzed against three pathway databases
(BBID, KEGG_Pathway, biocarta), three GO-term sources (BP/CC/MF_FAT), three
functional categories (cog_ontology, SP_PIR_Keywords, UP_seq_Feature), one dis-
ease source (OMIM) and 3 protein-domain database sources (Interpro, Pir-Superfamily,
Smart) using the Database for Annotation, Visualization and Integrated Discovery
(DAVID) version 6.7 (http://david.abcc.ncifcrf.gov/). This resulted in 82 annotation
clusters. The annotation cluster with the highest enrichment score of 73.4 was found for
the terms NOTCH signaling pathway (GOTERM_BP_FAT term ’NOTCH signaling
pathway’; adjusted p-value=1.4−100; SP_PIR_KEYWORDS term ’NOTCH signaling
pathway’; adjusted p-value=8.7−92) and the GOTERM_BP_FAT term ’cell surface re-
ceptor linked signal transduction’ (adjusted p-value=9.7−22).
Accordingly, the compiled NOTCH gene set is highly representative for the NOTCH
signaling pathway.
3.1.2 Acquisition of data, quality control and processing
In order to detect a putative NOTCH signature, mRNA gene expression profiling was
performed with HRS cell lines L428, L1236, KM-H2, HDLM-2, L540 and L540Cy and
with the non-Hodgkin cell lines Reh (pre-B cell line), Namalwa (Burkitt’s lymphoma,
BL) and SU-DHL-4 (diffuse large B cell lymphoma, DLBCL). The Affymetrix array
platform HG U133 Plus 2.0 was used. Biological replicates of cell lines (except for
L540 and L540Cy) were acquired at different times, as to account for biological variance
introduced through culturing cell lines over periods of time. From that point on, all
samples were processed at the same times and by the same person as to exclude the
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Array name/cell line and replicate number coding number
HDLM-2_1 1
HDLM-2_2 2
KM-H2_1 3
KM-H2_2 4
L1236_1 5
L1236_2 6
L428_1 7
L428_2 8
L540 9
L540Cy 10
Namalwa_1 11
Namalwa_2 12
Reh_1 13
Reh_2 14
SU-DHL-4 15
Table 3.1: Array codings
All arrays were assigned a coding-number from 1-15. These numbers were used for naming the arrays
in the quality assessment process.
possibility of introducing a batch effect. The second array for cell line SU-DHL-4 failed
and could not be used for any analysis. In table 3.1, the numerical coding for all arrays
is shown and will be used in the various quality assessment plots below.
Affymetrix default quality controls and RNA degradation plots
Looking at the Affymetrix quality plot of the data (figure 3.1(a)), the ratios of 3’-
positioned probes to 5’-positioned probes of both ACTIN and GAPDH show to be
according to quality standards. In case of GAPDH the ratio is centered around 0 and in
case of ACTIN the ratios are between 0 and 1. This finding is confirmed when looking at
the RNA degradation plots (figure 3.1(b)), no array shows 5’-positioned to 3’-positioned
probe-slopes being significantly different from the other slopes. The calculated inter-
array scaling factors and percentages of presence calls are uniformly distributed around
-1 and between ≈37-47%, respectively. However, the average background is not evenly
distributed, with a value of 133.26, array #12 shows significantly higher background
than any other array (the other arrays have values of around 50).
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Figure 3.1: Affymetrix array quality controls
Quality plots recommended by Affymetrix and RNA degradation plots of the arrays show, that
quality standards are met. GAPDH and ACTIN rations are of good quality for all arrays, as are the
scale-factors and presence calls (a). RNA degradation is present, yet for all arrays the degradation
slopes (b) are very similar.
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MA-, intensity-density- and intensity box-plots
In figure 3.2, MA-, intensity-density- and intensity box-plots are shown for all 15 arrays.
Except for array #12, MA-plots of all arrays show similar distributions of the data.
Array #12 shows M-values shifted up to values of around 2.0 (M values should be
centered around 0), indicating, that array #12 has over all higher intensities than all
the other arrays. This is confirmed when looking at intensity-density- and intensity
box-plots, where there is a clear shift of the distribution to higher intensities.
NUSE, RLE and PM/MM intensity distribution diagnostics
On the relative log expression (RLE) plot (see figure 3.3(a)), arrays’ median RLE is
centered around 0 and RLE values are evenly distributed across all arrays (both of which
are expected) except array #12, where the distribution is a little broader. Looking at the
normalized unscaled standard error (NUSE) plots (where the median standard error over
all arrays was set to 1, see figure 3.3(b)) all arrays center around 1 (which is expected)
except for arrays #1, #12 and #13.
Looking at the intensity distribution of perfect matches (PM) and mismatches (MM),
one notes that PM intensities are shifted to higher intensities when compared with the
mismatch intensity distribution (see figure 3.3(c)). This is expected as MM probes have
poorer hybridization than PM probes.
In summary, especially array #12 shows to be an outlier array in many aspects tested.
Array #13 also shows to slightly differ from the other arrays. A subsequent cluster
analyses should help to determine, whether background correction and normalization of
all arrays would result in the expected biological clustering of a main cHL cluster and a
main non-Hodgkin cluster.
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Figure 3.2: Quality assessment plots I
In (a) and (b), MA-plots show the similarity of each individual array to a pseudo-array calculated from
the mean-intensity of every probe on the Affymetrix HGU 133 Plus 2.0 platform. For arrays with good
quality, the expected distribution of values should center around the x-axis. The intensity-density- (c)
and intensity box-plots (d) reveal information about array-individual intensity distributions, the
spread of the distributions is expected to be more or less the same for all arrays, as is their median.
All quality plots shown here indicate, that array #12 shows intensities shifted to higher values than
seen for all other arrays.
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Figure 3.3: Quality assessment plots II
Shown are RLE (a), NUSE (b) and PM/MM (c) plots for arrays 1-15. The NUSE and RLE quality
plots shown here indicate, that array #12 shows quality problems.
Biological clustering
The cluster analysis in figure 3.4 was done after robust multi-array average (RMA)
background correction and quantile normalization of unprocessed data. It shows, that
our samples cluster according to their biological groups, even arrays #12 (Namalwa_2)
and #13 (Reh_1) cluster as expected with their biological replicates with a Pearson
correlation coefficient of ≈0.99. In respect of this result, it is assumed, that the technical
quality issues of array #12 and #13 are accounted for by the used processing approach.
This and the aim not to reduce statistical power by reducing sample numbers led to the
decision, to use all arrays for all further analyses.
3.1.3 Gene wise fitting of linear models
To determine genes significantly deregulated in cHL, gene-wise fitting of linear models
was performed using the LIMMA [139] framework. All 54675 features present on the
Affymetrix HGU 133 2.0 Plus array were used without applying any filters. The following
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Figure 3.4: Pearson cluster analysis of cell lines
Biological clustering (Pearson distance and complete linkage were used as clustering parameters) of all
15 arrays using data of all features present on the Affymetrix HG U133 Plus 2.0 platform. Note that,
where available, biological replicates cluster together. Moreover, there are two distinct biological
clusters: one non-Hodgkin sample cluster and one cHL sample cluster. This suggests, that there is a
substantial number of differentially regulated genes in between the two groups. It also confirms, that
processing accounts and adjusts for technical problems with array #12 (Namalwa_2).
linear model was used for fitting:
yi = 0 + x1HL + x2nHL + i (1)
where yi is the feature present in row i of the expression value matrix, x1 and x2 are
the estimators with xn ∈ R for each of the dummy regressors of the factor group (which
has two levels: HL and nHL). Models were forced through the origin, as no common
reference or population mean was assumed. In R pseudo-code this will reduce to:
yi = 0 + group (2)
43
3 Results
where group is the factor mentioned above.
Fold change in between groups was then calculated by multiplying an according con-
trast matrix with the calculated estimators of both group levels to get contrast esti-
mators. Contrast estimators were then used for calculation of p-values using moderate
t-tests [139]. Resulting p-values were adjusted to account for multiple testing using the
method of Benjamini and Hochberg [142].
All features showing at least a log2-fold change of ≥0.5 or ≤-0.5 and an adjusted
p-value of p≤0.05 were deemed significantly deregulated and thus were used for further
analyses. These limitations resulted in the identification of ≈4400 significantly deregu-
lated features in cHL.
3.1.4 Identification of a NOTCH signature
Principal Components Analysis
Data of the intensity values of all Affymetrix features representing genes of our NOTCH
gene set were extracted resulting in a high-dimensional 270×15 matrix. To reduce
dimensionality of this matrix to a visualizable level, unrotated Principal Components
Analysis (PCA) was applied. Principal component (PC) 1 accounts for 82%, PC2 for
7% and PC3 for 3% of data set variance. The factor loadings are plotted in figure 3.5.
As seen by this graphical representation, cHL samples are clearly separated from non-
Hodgkin B cell control samples, indicating the presence of a cHL specific NOTCH signa-
ture. This result also suggests, that the NOTCH signaling system is globally regulated
in a different manner in HRS cell lines than in non-Hodgkin cell lines. To address the
question whether the separation seen in the PCA analysis is due to chance or whether
it represents a true effect, Fisher’s Exact Test was applied with the counts of genes
that do or do not show statistically significant deregulation as defined in section 3.1.3.
63 of 270 features of our NOTCH gene set were deregulated according to the defined
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Figure 3.5: Principal Components Analysis of cell lines
Unrotated Principal Components Analysis was done with the intensities of 270 NOTCH associated
features measured in 10 HRS cell line samples and 5 non-Hodgkin cell line samples. cHL samples
separate from non-Hodgkin samples, suggesting, that cHL samples are characterized by a distinct
NOTCH signature.
limitations. The result of the Fisher test, p<10−10, shows that our NOTCH gene set is
highly significantly deregulated in cHL.
Extending the analyses to arrays from primary cases
As to gain more biological and statistical power and in order to substantiate our cell line
results, array data from the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/)
data set GSE12453 were analyzed [24]. From this data set, 12 primary cHL cases, 5
primary BL cases and 11 primary DLBCL cases were taken and merged with our dataset.
Assessing these data and our data in comparison there clearly is a batch effect present
(see figure 3.6), resulting in the necessity to account for this effect in all subsequent
analyses.
Quality assessment of the GSE12453 data was done separately, all arrays passed qual-
ity standards (a quality summary is given in Appendix B). Our dataset and the specified
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Figure 3.6: Batch effect detection in between datasets
Visualization of the intensity data of all features present on the used HGU 133 Plus 2.0 platform using
a boxplot representation (a) and a Pearson distance cluster analyses (b) using complete linkage were
performed. Note, that our data shifts to significantly higher intensity-distributions and that samples
do not cluster according to their biological groups, yet according to their technical batches. This
indicates the presence of a batch effect. All sample names starting with ’GSE’ were taken from data
set GSE12435. pHL, primary Hodgkin Lymphoma sample; pDLBCL, primary Diffuse Large B Cell
Lymphoma sample; pBL, primary Burkitt Lymphoma sample.
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data from GSE12453 were then processed together (RMA background-correction and
quantile normalization were applied). To account for the batch effect in the statistical
analyses, the linear model used for determination of differentially expressed genes was
subsequently extended to following R pseudo-code representation:
yi = 0 + group + batch (3)
where batch is a factor with two levels representing the batch of our data set or the data
from GSE12453, respectively. Adjustment of the data using linear models for batch effect
estimator determination and the subsequent batch-correction resulted in clustering of
the samples according to their biological groups (see figure 3.7).
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Figure 3.7: Cluster analysis after correction for the batch effect
The batch effect for each feature present on the used HGU 133 Plus 2.0 platform was estimated using
linear models and than corrected for. Note, that after correction for the batch effect, samples cluster
according to their biological groups. All sample names starting with ’GSE’ were taken from data set
GSE12435. pHL, primary Hodgkin Lymphoma sample; pDLBCL, primary Diffuse Large B Cell
Lymphoma sample; pBL, primary Burkitt Lymphoma sample.
Statistically significant differential expression of genes was then determined as de-
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scribed above. Altogether, ≈4300 of 54675 features were significantly deregulated in the
pooled cHL samples when compared with the non-Hodgkin samples. Again, Fisher’s
Exact test was performed with the data of all features of our NOTCH gene set. All to-
gether, 48 of 270 features of the NOTCH gene set were significantly deregulated. Fisher’s
exact test rendered this result to be significant with p<10−4.
586 4135
not signifcantly regulated features = 47272
Overlap Statistics:
- test universe={all features}
- expected overlap by chance = 264 features
- representation factor = 2.2
- p < 9.073-79
primary non-HL
vs. primary HL
non-Hodgkin cell line
vs. HRS cell lines
2682
(a)
10 15 48
not signifcantly regulated features = 197
Overlap Statistics:
- test universe={NOTCH associated features}
- expected overlap by chance = 5 features
- representation factor= 2.6
- p < 3.495-05
primary non-HL
vs. primary HL
non-Hodgkin cell line
vs. HRS cell lines
(b)
14 34 29
not signifcantly regulated features = 193
Overlap Statistics:
- test universe={NOTCH associated features}
- expected overlap by chance = 11 features
- representation factor= 3.0
- p < 2.9-15
merged data non-HL
vs. merged data HL
non-Hodgkin cell line
vs. HRS cell lines
(c)
Figure 3.8: Overlap of significantly deregulated features in between different data sets
Venn diagrams are shown for (a) the comparison of all significantly deregulated features in primary
and cell line samples, respectively. (b) shows the same comparison as in (a) for all NOTCH associated
features and (c) shows the overlap of significantly deregulated NOTCH associated features when
comparing cell line data and the merged data sets. The significance of any overlap was determined by
calculating the exact hypergeometric probability. The number of features n expected to overlap by
chance was calculated using the numbers a and b representing the count of features in either set used
for the comparison and the total number of features N: n=(a×b)/N.
Comparing the overlap of NOTCH gene set deregulation in the different data
sets used
As to assess in how far deregulation of all genes and of the NOTCH gene set is similar in
between the disjunct cell line, primary sample and merged data sets, the overlapping sets
of their significantly deregulated genes was determined. As seen in figure 3.8, there is
a significant intersection of significantly deregulated genes when all features of the used
HGU 133 Plus 2.0 platform are analyzed, when comparing primary samples to cell lines.
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The overlapping set of significantly deregulated NOTCH associated genes is significant
for the comparison of primary to cell line data sets as well as for comparison of cell
line data to the merged data set. This implies, that quality and magnitude of NOTCH
deregulation is very similar in HRS cell lines and cHL primary cases. Appendix C lists
the NOTCH gene set and the regulation of each feature in the different comparisons.
3.1.5 Gene Set Enrichment Analysis (GSEA)
For GSEA analysis we used – in addition to our NOTCH gene set – two publicly avail-
able NOTCH gene sets from the Molecular Signatures Database of the Broad Institute
(http://www.broadinstitute.org/gsea/). Analyzing the data set with GSEA using our
NOTCH gene set and the publicly available NOTCH gene sets shows that all sets are
highly enriched as seen in figure 3.9 and table 3.2.
Figure 3.9: NOTCH Gene Set Enrichment Analysis
GSEA analysis plot for the NOTCH gene set developed in this study. Array features were ranked
according to their signal to noise ratio and enrichment was calculated according to the algorithm
developed by [140]. Cell line data was used as input. Note, that there is a significant enrichment of
NOTCH associated genes that are up–regulated (e.g. MAML2 and NOTCH2, i.e. positive regulators
of NOTCH signaling) or down–regulated in cHL (e.g., DTX1, i.e. a negative regulator of NOTCH
signaling).
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Gene Set Name Feature Count Normalized Enrichment Score FDR q-value
NOTCH (Köchert et al.) 270 1.34 0.016
NOTCH_SIGNALING_PATHWAY 39 2.10 0.000
NOTCHPATHWAY 16 1.76 0.002
Table 3.2: GSEA results with different NOTCH gene sets
3.1.6 Conclusions from statistical analyses of array data
Taken together, the statistical analyses of array data gained from HRS and non-Hodgkin
cell lines in combination with array data from primary cHL and non-Hodgkin cases
showed, that there is a statistically significant deregulation of the NOTCH signaling
pathway in cHL. The quality of this deregulation is not directly concludable from the
analyses, as the NOTCH gene set members that show to be deregulated in cHL may
have different impacts with the outcome possibilities:
a) positive regulation of NOTCH signaling
b) negative regulation of NOTCH signaling
c) direct/indirect result of activation/inactivation of NOTCH signaling
Thus, the next step was to combine the available context knowledge about NOTCH
signaling with the results of the statistical analyses, as to draw conclusions about the
actual characteristics of the deregulation of the NOTCH signaling system in HL.
3.1.7 Identifying top hits within the NOTCH gene set —
hypothesis generation
To identify genes of high interest for further analyses, different parameters were taken
into account:
• log2-fold change (log2intensity(cHL)-log2intensity(non-Hodgkin))
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• adjusted p-values calculated from moderate t-tests
• GSEA rank metric scores
• relevance of gene for the NOTCH signaling pathway
Table 3.3 shows the top 10 NOTCH associated genes and the values of the mentioned
parameters. The analysis is in good agreement with studies published by Jundt et al.
and Kapp et al.: our analyses shows a significant up–regulation of NOTCH2 [55, 56]
and a significant down–regulation of an inhibitor of NOTCH signaling, DTX1 [74]. The
analyses moreover have shown, that the NOTCH associated genes are deregulated in
cHL in a manner, that — according to todays knowledge about NOTCH signaling —
will result in aberrant up–regulation of this pathway. Looking at table 3.3, one finds that
MAML2, one of the three essential co-activators of NOTCH signaling, is highly (23.6-
fold) up–regulated in cHL. This significant up–regulation of MAML2 is also found when
analyzing the primary sample and merged data sets (see appendix C, Affymetrix Probe
ID 235457_at). With respect to their subjective importance for NOTCH signaling and
the degree of their deregulation, none of the other NOTCH associated genes found to
be deregulated has such a high impact on the activation of NOTCH signaling.
Thus, MAML2 was determined to be the most important gene of interest for further
mechanistic and functional analyses of NOTCH signaling in cHL.
There are various other genes involved in the processing of the NOTCH receptors, such
as ADAM10 (responsible for S2-cleavage of NOTCH receptors) and members of the
γ-secretase complex (PSEN1, PSEN2) which — according to these analyses — show
to be up–regulated in cHL. Their up–regulation may also be interpreted as facilitat-
ing mechanism for NOTCH cleavage processes. In turn, the found up–regulation of
NOTCH2 as described in [55, 56], also points into the direction of aberrant activation of
the NOTCH signaling pathway in cHL. However, interplay of different NOTCH-ligands
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Gene symbol log2-fold change adjusted p-value GSEA rank metric score NOTCH association
GATA3 6.38 2.5×10−5 1.86 c
MAML2 4.56 1.0×10−5 1.70 a
PSEN2 3.12 6.0×10−5 1.33 a
NOTCH2 2.97 0.01 1.54 a
PSEN1 1.09 0.03 1.34 a
SEL1L 1.60 0.03 1.26 unknown
ADAM10 0.77 0.05 1.00 a
DTX4 -1.93 0 -1.44 b
TCF3 -1.40 0 -1.73 c
DTX1 -4.00 0 -3.33 b
Table 3.3: 10 top hits - deregulated NOTCH genes in cHL
with different NOTCH receptors is poorly understood to date. The mere up–regulation
of a NOTCH receptor is therefore not as important as the deregulation of an essential
co-activator, such as MAML2, that by itself will activate NOTCH signaling with any
cleaved NOTCH receptor [96, 95] and without whom NOTCH transcriptional activation
may be impossible.
3.1.8 Assessing the expression status of Mastermind-like family
members MAML1, MAML2 and MAML3
To verify the findings of the array analyses, the mRNA expression status of the various
NTC components of HRS compared to non-Hodgkin cell lines was assessed using qPCR.
Special emphasis was put forward on the analyses of the members of the Mastermind-like
family. As seen in figure 3.10, relative quantification of the MAML family members is
in accordance with the array analyses.
MAML1 shows no significant regulation in between HRS and non-Hodgkin cell lines, it
is expressed at robust levels in all cell lines tested.
MAML2 in opposite shows a significant up–regulation in HRS cell lines which in relative
comparison to the non-Hodgkin cell line Reh is up to 8-fold. The highest, relative levels
of MAML2 are found in the cell lines L1236 (5.5-fold up regulation), L591 (6-fold up
regulation) and HDLM-2 (8-fold up regulation). All tested HRS cell lines show at least
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2-fold up regulation of MAML2 compared to Reh cells. Within the non-Hodgkin cell
lines, Reh shows the highest levels of MAML2. Namalwa has around 0.1-fold MAML2
levels when compared to Reh, BL-60 around 0.3 fold-levels and BJAB and SU-DHL-4
show MAML2 CT values that are at the level of undetectability (CT=34-35).
In turn MAML3 qPCR shows a slight, yet significant up–regulation of MAML3 mRNA
levels in non-Hodgkin cell lines. Reh and BJAB cells show the highest MAML3 levels
in all cell lines tested, in cHL only cell lines L1236 and KM-H2 show non-Hodgkin cell
line comparable MAML3 mRNA levels. All other HRS cell lines tested show MAML3
CT values close to the level of undetectability (CT=33-35).
To get an impression of the relative abundance of the different MAML members in HRS
cell lines, ∆CT values were analyzed and plotted in figure 3.10(b). Relative abundance
of MAML2 mRNA (median ∆CT of ≈5) is thus significantly higher than the mRNA
levels of MAML1 (median ∆CT of ≈9.3) and MAML3 (median ∆CT of ≈15.5). This
is suggestive of the quantitative importance of MAML2 in the suspected deregulation of
NOTCH signaling in cHL.
Validating MAML members qPCR data on protein level
Next, MAML1, MAML2 and MAML3 protein levels were assessed in our cell line panel
in order to validate qPCR analyses. As seen in figure 3.11, western blot analyses confirms
the qPCR data.
All cell lines tested show expression of MAML1. In case of the HRS cell lines, L428,
L1236 and L591 MAML1 expression is only weak, in opposite HRS cell lines KM-H2,
L540 and L540Cy show robust expression. As for the non-Hodgkin cell lines, Reh and
Namalwa show robust expression, whereas BL-60, BJAB and SU-DHL-4 show weak
expression.
MAML2 protein is highly expressed in all HRS cell lines tested. In Reh, BL-60 and
BJAB there is only weak expression and in cell lines Namalwa and SU-DHL-4 expression
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Figure 3.10: qPCR quantification of all three Mastermind-like family members in cHL
and non-Hodgkin cell lines.
mRNA levels of all human Mastermind-like family members were quantified relative to GAPDH using
qPCR (a). There is robust expression of MAML1 in all cell lines tested, with little differences within
them. In opposite, MAML2 is highly up–regulated in all HRS cell lines tested, when compared with
non-Hodgkin cell lines. MAML3 mRNA levels are slightly higher in non-Hodgkin cell lines than in
cHL. (b) is a box-and-whisker plot presentation of HRS cell line ∆CT values for all MAML members
and shows, that there is significantly more MAML2 mRNA present in cHL than MAML1 or MAML3.
Efficiencies of all primer pairs used was 91%±1.3%, allowing for this estimation of comparative
MAML abundance. Error bars denote 95% confidence intervals (a), Black bars: HRS cell lines, empty
bars: non-Hodgkin cell lines. *:p < 0.001,
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is not detectable.
MAML3 protein levels, as seen in the according qPCR analysis, vary substantially
across different cell lines. In regard to the HRS cell lines, MAML3 protein is detectable
in L1236, KM-H2, L540 and L540Cy. The non-Hodgkin cell lines Reh and BJAB show
high levels of MAML3, whereas Namalwa, BL-60 and SU-DHL-4 show weak expression.
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Figure 3.11: Western Blot analyses of MAML members
Western blot analyses of MAML1, MAML2 and MAML3 protein using whole cell extracts is in good
agreement with qPCR analyses. MAML1 is expressed in all cell lines tested without there being a
significant difference of expression levels in the biological groups, cHL and non-Hodgkin. Contrarily,
MAML2 is highly expressed in HRS cell lines, whereas in non-Hodgkin cell lines there is only weak or
barely detectable expression. MAML3 protein levels are somewhat up–regulated in non-Hodgkin cell
lines, in cHL, only cell line KM-H2 shows high MAML3 protein levels. β-actin was analyzed as control.
Since only few data regarding MAML2 expression in human lymphoid cells were avail-
able, MAML1, MAML2 andMAML3 mRNA expression and MAML2 protein expression
was determined in CD19+ B cells and CD3+ T cells. MAML1 and MAML3 mRNA is
expressed at robust levels in all cell types tested. Contrarily, MAML2 mRNA is most
prominently expressed in the HRS cell line L428 and primary CD3+ T cells whereas
there is no expression in the non-Hodgkin cell line Namalwa and very weak expression
in CD19+ B cells (see figure 3.12(a)). MAML2 protein was strongly expressed only in
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CD3+ T cells, whereas it was hardly detectable in CD19+ B cells, (see figure 3.12(b)).
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Figure 3.12: MAML member expression in primary B and T cells
The mRNA expression status of all human MAML members in primary CD3+ T and CD19+ B cells
was assessed using sqPCR (a). GAPDH was analyzed as control. (b) Western blot analysis using
whole cell lysates. MAML2 protein levels were assessed in primary CD19+ B cells and CD3+ T cells
isolated from two independent tonsils of healthy donors. As comparison, HRS cell line L428 and
non-Hodgkin cell line Namalwa are shown. In CD3+ T cells there is robust MAML2 expression
comparable to levels found in L428. In comparison, there is only very weak expression of MAML2 in
CD19+ B cells, which also might be the result of remaining technical T cell contamination of the
samples. These results imply that MAML2 expression is normal for T cells and is not normal for B
cells. β-actin was analyzed as control.
3.1.9 MAML2 immunohistochemistry of primary material
To confirm the cell line data in primary material, immunohistochemistry was performed
in non-neoplastic lymphoid tissue and 180 B cell-derived primary human lymphoma
cases. This was done for MAML2 only, and not the other MAML members, as the
data shown and analyses done so far show MAML2 to be the significantly deregulated
MAML co-activator in cHL. In contrast, MAML1 and MAML3 are not significantly
deregulated and thus — in regard to the scope of this study — it was decided not to
perform immunohistochemistry of these MAML members.
In several B cell-derived primary human lymphoma cases we detected high levels of
MAML2 expression. In cHL, 30 of 61 cases stain highly positive for MAML2 (see figure
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3.13), in B-ALL 8 of 8 cases stained positive and in MCL 4 of 10 cases stained positive
for MAML2. In the described cases, staining was found to be cytoplasmatic and nuclear.
In contrast, B cells of non-neoplastic lymphoid tissue did not stain positive for MAML2.
Some exemplary stainings are presented in figure 3.13, table 3.4 shows a summary of the
findings for all B-cell associated malignancies stained. In summary, these data show, that
MAML2 expression in various B cell-derived primary human lymphomas is unusually
high when compared to normal B cells of tonsillar origin. The results moreover suggest,
that aberrant, high-level MAML2 expression may play an important pathogenic role in
various B cell derived malignancies.
cHL
cHL
cHL
tonsil
MCL
B-ALL
Figure 3.13: MAML2 Immunohistochemistry
The analysis of non-neoplastic lymphoid tissue and 180 B cell-derived primary human lymphoma
cases by MAML2 immunohistochemistry revealed, that MAML2 is not expressed in normal B cells.
All tonsils from healthy donors (here, 1 representative case is shown) did not show MAML2 staining
of their B cells, only Macrophages and Dendritic cells stained positive. In opposite ≈50% of all cHL
cases stained highly positive for MAML2. Here, three representative cHL cases are shown, arrows
point to cHL cells. Massive MAML2 staining is also found in B cell lymphoblastic leukemia and
Mantle cell lymphoma (one representative case of each malignancy is shown).
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Disease type ≥90% cells 50-90% cells 0-49% cells all cells pos. cases/pos. pos. pos. neg. cases examined
B lymphoblastic leukemia 7 1 0 0 8/8
B cell chronic
lymphocytic leukemia
2 0 3 2 5/7
Lymphoplasmacytic lym-
phoma
2 0 2 3 4/7
Plasma cell myeloma 0 0 2 6 2/8
Nodal marginal zone lym-
phoma
3 0 1 6 4/10
Extranodal marginal
zone lymphoma
0 4 1 5 5/10
Follicular lymphoma (FL),
grade 1
0 2 1 5 3/8
FL, grade 2 1 0 0 7 1/8
FL, grade 3a 0 0 0 8 0/8
FL, grade 3b 0 0 2 6 2/8
Mantle cell lymphoma 3 0 1 6 4/10
DLBCL, GCB type 0 1 1 6 2/8
DLBCL, non-GCB type 0 1 5 4 6/10
Burkitt’s lymphoma 0 0 1 8 1/9
cHL 25 2 3 31 30/61
Table 3.4: MAML2 Immunohistochemistry of 180 B cell-derived primary human lym-
phoma cases
pos.: positive; neg.: negative
3.1.10 Quantification of NOTCH receptors, NOTCH ligands and
CSL in HRS- and non-Hodgkin cell lines
As the high-level expression of MAML2 alone would not suffice for activation of the
NOTCH signaling pathway, assessment of NOTCH receptor mRNA and protein expres-
sion was of vital importance for a thorough characterization of the cHL-specific NOTCH
signaling system. Also, as to get a complete picture of the expression status of the essen-
tial components composing the NTC (see above), the mRNA expression of all canonical
NOTCH ligands was quantified using qPCR and the mRNA expression of CSL was
assessed by sqPCR.
These data were of great importance in order to systemically specify the NOTCH path-
way in the cHL context.
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qPCR analyses of NOTCH receptors in cHL
In figure 3.14, the results of qPCR quantification of all human NOTCH receptors is
shown. NOTCH1 is expressed in all HRS cell lines (except L1236) at levels that are
found in the tested non-Hodgkin cell lines. Levels are slightly higher than in the non-
Hodgkin cell lines in KM-H2, L591 and HDLM-2.
Confirming earlier studies [55, 56], NOTCH2 levels are up to 4-fold higher (L1236) in
HRS cell lines than in non-Hodgkin cell lines. Within the HRS cell panel, L540 and
L540Cy show the lowest levels of NOTCH2, however, these are still higher than in
Namalwa, BL-60, BJAB and SU-DHL-4.
NOTCH3 mRNA is detected in almost all cell lines tested at very low levels (except
HRS cell line L1236) and hardly detectable in KM-H2 and L591. In case of NOTCH4
mRNA, only HDLM-2 and BJAB show levels that are well detectable, whereas all other
cell lines tested, have NOTCH4 CT values close to undetectability.
Analyses of NOTCH receptor protein expression in HRS cell lines
To verify qPCR data of NOTCH receptor mRNA expression on protein level, we per-
formed western blot analyses of all human NOTCH receptors in HRS and non-Hodgkin
cell lines. The according analysis for NOTCH1 was extended to assessment of the ac-
tivation status of this particular receptor and is shown below in section 3.1.11. The
analyses done for NOTCH2-4 are shown in figure 3.15. They confirm the qPCR data
shown above. NOTCH2 is expressed at high levels in all HRS cell lines and is weakly
expressed in non-Hodgkin cell line Reh and merely detectable in all other non-Hodgkin
cell lines (figure 3.15(a)). No NOTCH3 (figure 3.15(b)) or NOTCH4 (figure 3.15(c))
protein expression is detectable in any cell line tested.
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Figure 3.14: Expression status of NOTCH receptors in cHL
Quantification of all human NOTCH receptors was measured relative to GAPDH using qPCR. In the
HRS cell lines analyzed, NOTCH1 is expressed at levels comparable to those found in non-Hodgkin
cell lines. Only L591 cells show NOTCH1 levels that are substantially higher (≈2.5-fold of Reh levels)
than in non-Hodgkin cell lines. Confirming earlier studies [55], NOTCH2 is significantly up–regulated
in HRS cell lines, e.g. L1236 have ≈4-fold more NOTCH2 than Reh cells. For the receptors NOTCH3
and NOTCH4 no systematic regulation or differential expression in between the two biological groups
is detectable. Error bars denote 95% confidence intervals, black bars: HRS cell lines, empty bars:
non-Hodgkin cell lines.
qPCR analyses of NOTCH ligands
Next, the mRNA levels of all canonical NOTCH ligands were assessed. As shown in
figure 3.16(a), JAG1 is expressed at low levels in HRS cell lines with the exception of
L591, where expression is at least 25-fold higher then in according non-Hodgkin cell lines.
The non-Hodgkin cell line Namalwa also shows up to 5-fold higher levels of NOTCH1
mRNA than, e.g. cell line Reh.
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Figure 3.15: NOTCH receptor protein expression
Whole cell lysates were used for western blot assessment of NOTCH receptor protein expression in
HRS- and non-Hodgkin cell lines. (a) shows protein expression of NOTCH2. Note, that it is highly
expressed in HRS cell lines in comparison to non-Hodgkin cell lines and is in agreement with
previously published data [56]. Neither NOTCH3 (b), nor NOTCH4 (c), show protein expression in
any cell line analyzed. In case of these two receptors, whole cell lysates of NIH3T3 cells transduced
with a control construct (mock) or an viral expression construct coding for NIC3 and NIC4,
respectively, were used as protein control. β-actin was analyzed as control.
JAG2 in turn is highly up–regulated (up to 100-fold) in cHL, especially in the cell
lines L1236, KM-H2 and HDLM-2. For the ligands DLL1, DLL3 and DLL4, expression
levels are low across all cell lines tested (see figure 3.16(b)). No systematic differential
regulation is observed when HRS and non-Hodgkin cell lines are compared.
mRNA expression status of CSL
As CSL is the canonical transcription factor necessary for transcriptional activation
mediated by NIC and MAML proteins, its mRNA expression status was determined in
HRS- and non-Hodgkin cell lines. As seen in figure 3.17, CSL mRNA expression was
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Figure 3.16: Expression status of NOTCH ligands in cHL
qPCR quantification of the canonical NOTCH ligands JAG1 and JAG2 (a), DLL1, DLL3 and DLL4
(b) in HRS and non-Hodgkin cell lines relative to GAPDH. Note, that especially JAG2 is significantly
up–regulated in HRS cell lines. For all other ligands, there is no systematic, group-dependent
regulation observable. Error bars denote 95% confidence intervals, black bars: HRS cell lines, empty
bars: non-Hodgkin cell lines.
detectable at robust levels in all cell lines analyzed.
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Figure 3.17: mRNA expresseion of CSL
CSL mRNA expression was assessed using sqPCR. Primers were designed to amplify all four known
human splice variants. GAPDH was analyzed as control.
3.1.11 Cleavage status of NOTCH1
In order to determine whether the NOTCH1 signaling pathway is activated in HRS cell
lines in terms of NOTCH receptor cleavage, western blot analyses were performed with
whole cell and nuclear extracts of various HRS and non-Hodgkin cell lines. Confirming
previous studies [56], the NOTCH1 receptor is expressed at robust levels in all HRS cell
lines tested except for L1236 (this being in accordance with results from section 3.1.10).
However, it is also expressed in non-Hodgkin cell lines (figure 3.18, upper panel). This
was assessed by usage of an antibody detecting NOTCH1 and NOTCH1TM .
A different antibody specific to the N-terminal S3 cleavage site of NIC1 was then used
to assess the actual cleavage status of NOTCH1, as a positive control the T-ALL cell
line SUP-T1 was used. This cell line shows constitutive NOTCH1 signaling due to a
t(7;9)(q34;q34.3) translocation [143] which results in the constitutive expression of NIC1.
As seen in figure 3.18 (lower panel), except BL-60, every cell line tested shows some level
of NIC1 which is enriched in the nucleus when compared to whole cell extracts. In case
of cHL, cell lines KM-H2, L591 and HDLM-2 show high levels of activated NOTCH1,
all other HRS cell lines show low to medium levels. In the non-Hodgkin cell lines, BJAB
and SU-DHL-4 cells show the highest levels of NIC1.
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Figure 3.18: Expression and cleavage status of the NOTCH1 receptor
Western blot analyses of NOTCH1 receptor expression and NOTCH1 cleavage in HRS and
non-Hodgkin cell lines. NOTCH1 is expressed in all cell lines analyzed except L1236 (upper panel). In
nuclear extracts, there is cleaved NOTCH1 (NIC1) in all cell lines analyzed, except BL-60. The
T-ALL cell line SUP-T1 (which constitutively expressed NIC1) was used as control for positioning of
the NIC1 protein band. HRS cell lines KM-H2, L591 and HDLM-2 show high levels of NIC1. In
opposite, L1236 NIC1 levels are barely detectable. HEK293 cells transfected with a control-vector
(mock) or a NIC1-flag (this NIC1 construct does not possess the native NOTCH1 S3-cleavage epitope)
expression vector were used for testing the specificity of the NIC1 specific antibody. β-actin or PARP1
were analyzed as control. ∗, antibody recognizing NOTCH1TM ;∗∗, antibody specifically recognizing
the N-terminus of NIC1, which becomes accessible only after S3 cleavage.
3.1.12 Assessing the potential of MAML2 to activate NOTCH
signaling
We next wanted to assess the potential of MAML2 to super-induce NOTCH1 dependent
transcription in a system where NIC1 is present to some degree. To this end we used a
NOTCH reporter assay that has been described in previous studies as detection system
for NOTCH transcriptional activation [144]. The HES1 promotor region (-194 bp to
+160 bp) was cloned in front of a firefly luciferase using the pGL2 vector as backbone
(HES1 being a well characterized NOTCH target gene [144]). A thymidine-kinase driven
luciferase construct was used for signal normalization. HEK293 cells were transfected
with these reporter-constructs and different combinations of constructs coding for NIC1
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and MAML2. HEK293 cells show low levels of endogenous MAML2 and NIC1. As seen
in figure 3.19, there is a 3-fold activation of the NOTCH-reporter construct in HEK293
cells when transfected with NIC1, ectopic expression of MAML2 in turn leads to a 1.9-
fold induction of the reporter construct. Ectopic expression of MAML2 and NIC1 leads
to a 5.5-fold super-induction.
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Figure 3.19: NOTCH1 reporter assay in HEK293 cells
HEK293 cells were used for a dual luciferase-based NOTCH reporter assay. Cells were transfected
with different constructs and lysed 48 hours after transfection. In this cellular context, NIC1 as well
as MAML2 activate this reporter system significantly, the combination of both expression constructs
results in a super-induction of the reporter. Expression of all constructs was monitored using western
blotting with whole cell lysates, β-actin was used as control. Error bars denote standard deviation.
**:p<0.001
To extend this model system, we used the lymphatic cell line SUP-T1. This cell line
shows only very weak MAML2 protein expression and high levels of NIC1 (see section
3.1.11). Thus we aimed to determine the effect of ectopic MAML2 expression on this
system with inherent, aberrant NOTCH1 activity. Again, ectopic expression of NIC1
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drives the reporter even more then just the already present levels of endogenous NIC1 (2-
fold). This effect is observed to the approximately same extend (2.3-fold) when MAML2
is ectopically expressed. A 5.2-fold induction of the reporter is the result of ectopical
expression of both members of the NOTCH transcription machinery (see figure 3.20).
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Figure 3.20: NOTCH1 reporter assay in SUP-T1 cells
SUP-T1 cells were used for a dual luciferase-based NOTCH reporter assay. Cells were transfected
with different constructs and lysed 48 hours after transfection. In this cellular context, NIC1- as well
as the MAML2-construct activate this reporter system significantly, the combination of both
expression constructs results in a super-induction of the reporter. Expression of all constructs was
monitored using western blotting with whole cell lysates, β-actin was used as control. Error bars
denote standard deviation. **:p<0.001
From these data we concluded, that in a system, where NIC1 is present, high-level ex-
pression of MAML2 suffices to super-induce the NOTCH signaling pathway. Taken to-
gether, the data accumulated by then stated, that every core component of the NOTCH
signaling pathway is present in cHL. As NOTCH1 is also present in its activated form,
this argues for B cell inappropriate activation of the NOTCH signaling pathway in cHL,
which might be essentially mediated by high-level expression of MAML2.
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3.1.13 Establishing knockdown of MAML2 in HRS cell lines
To evaluate the contribution of MAML2 to cHL specific NOTCH signaling, we wanted
to test the effect of MAML2 knockdown on different biological readouts. Initial attempts
to do so by transfection of Dharmacon ON-TARGETplus SMARTpool MAML2 siRNA
were confounded by weak MAML2 knockdown, especially when looking at MAML2
protein levels over time course. To overcome this limitation three of the sequences from
the MAML2 siRNA SMARTpool were cloned into the pSUPER expression vector, which
results in the efficient production of shRNA transcripts (hereafter these constructs are
referred to as shMAML2). Almost complete knockdown of MAML2 was achieved using
this approach (figure 3.21) over up to 72 hours of time. A respective control shRNA
(hereafter referred to as shControl) construct was kindly provided by Dr. Martin Janz
as described in [136].
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Figure 3.21: shRNA based knock down of MAML2
L428 and L519 cells were transfected with GFP and pSuper based constructs coding for shControl
(targeting the firefly luciferase gene) or shMAML2 (targeting human MAML2). After 48 hours, GFP+
cells were FACS-enriched, lysed and total protein extracts were analyzed using western blotting.
MAML2 protein levels were knocked down almost completely in both L428 and L591. β-actin was
analyzed as control.
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3.1.14 cHL specific target gene regulation through MAML2
mediated NOTCH signaling
To identify NOTCH target genes that may be cHL-specifically deregulated through
MAML2 mediated NOTCH signaling, we screened our NOTCH gene set for deregulated
NOTCH target genes.
Re-screening the NOTCH GSEA analysis from section 3.1.5 (because of its less con-
servative statistical approach, GSEA also detects deregulated genes not detected by
robust single-gene statistics), we found the NOTCH target genes HES7 and HEY1 to be
part of the GSEA leading edge with a rank metric score of 0.75 and 0.66, respectively.
Deregulation of these genes were subsequently tested with the known cell panel shown
in figure 3.22 (a) using sqPCR. In comparison to non-Hodgkin cell lines, HES7 mRNA
is found at high levels in all HRS cell lines. In opposite, it is completely lacking in
the non-Hodgkin cell lines. In case of HEY1, mRNA levels are robust in all HRS cell
lines (except HDLM-2) and in non-Hodgkin cell lines comparatively low (Namalwa and
BJAB) or lacking (Reh, BL-60, SU-DHL-4).
To assess the potential regulation of these two genes by MAML2 dependent NOTCH
signaling, their mRNA levels were determined 48 hours after transfecting L428 and L591
with shControl or shMAML2 constructs (see figure 3.22 (b)). In L428, knockdown of
MAML2 resulted in HES7 levels significantly reduced to 58% of the respective control
sample and in case of HEY1 to 37%. In L591 this significant reduction was 51% for HES7
and 63% in case of HEY1 in comparison to according control samples. These results
indicate, that high-level MAML2 expression in HRS cell lines is essential for HES7 and
HEY1 mRNA expression. This argues in favour for aberrant NOTCH activation through
MAML2 in cHL.
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Figure 3.22: Expression status of HES7 and HEY1
Analyses of HES7 (a, upper panel) and HEY1 (a, lower panel) mRNA expression were done using
sqPCR. Compared to non-Hodgkin cell lines, HES7 is highly expressed in HRS cell lines except in
L591 and HDLM-2, which show comparatively low levels. In non-Hodgkin cell lines, no HES7 mRNA
was detectable. HEY1 also is expressed at high levels in HRS cell lines except HDLM-2 when
compared to its weak expression in non-Hodgkin cell lines (Namalwa and BJAB). HEY1 mRNA is
barely detectable in non-Hodgkin cell lines Reh, BL-60 and SU-DHL-4.
(b) L428 and L591 cells were transfected with GFP and shControl or shMAML2. GFP+ cells were
FACS-enriched after 48 hours. Subsequent qPCR analyses showed, that HES7 as well as HEY1
mRNA levels are significantly reduced after MAML2 knockdown. GAPDH was used as internal
control or for relative quantification in qPCR, respectively. Error bars denote 95% confidence intervals.
*:p<0.05; **:p<0.001
3.1.15 MAML2-mediated NOTCH activity is essential for HRS cell
line proliferation
As further functional test of MAML2 mediated NOTCH signaling and in order to assess
its biological significance, the proliferation potential of HRS cell lines L428 and L591 and
the non-Hodgkin cell line BJAB (which does show high levels of activated NOTCH1,
see figure 3.18) in dependency of MAML mediated NOTCH signaling was investigated
using two different approaches described below.
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Inhibition of cHL specific NOTCH signaling via transient knock down of MAML2
First, MAML2 was knocked down in cell lines L428 and L591 using the shMAML2
constructs described above. Though BJAB cells do not express MAML2 (see figure
3.11), they were also transfected with shMAML and shControl as to determine whether
possible effects on proliferation are due to off-target effects or general toxicity of the
shRNA constructs used. Proliferation was measured via 3H-thymidine incorporation.
As shown in figure 3.23(a), proliferation of L428 is reduced significantly down to 76% of
the respective control and in case of L591 down to 51% of the respective control. BJAB
cells were not affected significantly, implying, that in the B cell background of the cell
lines used, treatment with the shMAML constructs used does not generally result in
reduced proliferation. In turn, MAML2 expression thus essentially contributes to the
proliferation potential of HRS cell lines.
Inhibition of NOTCH signaling via usage of a competitive peptide inhibitor
To test whether competitive inhibition of MAML protein binding to the NIC/CSL/DNA
(pre-NTC) complex would also lead to reduced proliferation of HRS cell lines L428 and
L591, a dominant negative version of MAML1 fused to pEGFP (DnMAML1) was used to
transfect these cell lines. DnMAML1 is a truncated version of native MAML1 consisting
only of amino acids 13 to 74. This version of MAML1 thus lacks the transactivation
domains necessary for a transcriptionally active NTC. When ectopically expressed in a
cell it will competitively inhibit native MAML binding to the NIC/CSL/DNA complex
[135]. DnMAML1 binds to the pre-NTC with a seemingly higher affinity then any native
MAML protein and therefore is a potent and specific inhibitor of NOTCH signaling
[135, 100, 145].
Transfection of L428 with DnMAML1 resulted in proliferation reduced to 73% when
compared to the respective control (pEGFP). Proliferation of L591 was also reduced
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Figure 3.23: Impact of NOTCH inhibition
L428, L591 and BJAB cells were transfected with (a) GFP and shControl or shMAML2 constructs or
(b), with GFP or DnMAML1-pEGFP. GFP+ cells were FACS-enriched after 48 hours and
subsequently used for 3H-thymidine-incorporation based proliferation assays. Assays were harvested
and measured 96 hours after initial transfection.
As seen in (a), knockdown of MAML2 protein results in significant reduction of proliferation of HRS
cell lines L428 and L591, the same is the case when NOTCH signaling is inhibited using the
competitive DnMAML1-pEGFP construct. Contrarily, BJAB cells are not affected by either
construct, implying that treatment with these constructs does not generally affect proliferation of cells
with a B cell background. Error bars denote standard deviation.
*:p<0.01; **:p<0.001; n.s., not significant.
down to 68% of the respective control (see figure 3.23(b)). In opposite, proliferation of
BJAB cells tranfected with DnMAML1-pEGFP was not influenced when compared to
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the control, despite the fact, that BJAB cells do show high levels of NIC1 (see figure
3.18). One may conclude, that in the specific BJAB context NOTCH1 signaling is not
essential for the proliferation potential. Also, this result shows, that the treatment with
DnMAML1-pEGFP is not generally toxic for cells with a B cell background.
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3.1.16 Short summary and conclusions, part I
Below, the most important aspects and conclusions of part I of this work are listed:
• Statistical analyses of high-dimensional microarray data have shown, that cHL
is characterized by a distinct and statistically significant NOTCH signature. It
moreover revealed, that the whole gene-set defined NOTCH signaling system is
differentially regulated in cHL when compared with primary samples and non-
Hodgkin cell lines of other B cell associated malignancies.
• This signature is dominated by the essential NOTCH co-activator MAML2.
• A significant number of other NOTCH associated genes contributes to this signa-
ture (see appendix C).
• In contrast to normal tonsillar B cells, high MAML2 expression was detectable in
malignant cells of various primary lymphomas.
• In a system, where activated NOTCH receptors are present, high-level MAML2
expression suffices to super-induce NOTCH mediated transcription.
• NOTCH signaling is aberrantly active in HRS cell lines in a cell-autonomous man-
ner.
• NOTCH signaling is in part essential for HRS cell line proliferation and context
specific NOTCH target genes.
• High-level MAML2 protein expression is partly essential for HRS cell line prolif-
eration and context specific NOTCH target genes.
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3.2 Part II: Targeting of the NOTCH transcriptional
complex
As mentioned above, pathologic deregulation of NOTCH signaling is found in a wide
variety of diseases. Treatment possibilities are sparse, especially when components of
the NOTCH signaling system are deregulated by mutations or deletions (see section
1.2.2). Part I of this work has shown, that high-level expression of the NOTCH co-
activator MAML2 provides an additional mechanism, how NOTCH signaling may be
pathologically deregulated through deregulation of NTC components. As this deregula-
tion takes place at the step of NTC assembly, it was obvious to use the NTC assembly
as therapeutic target.
We thus were aiming to provide new ways of targeting NOTCH signaling at its very core,
namely the NTC assembly process.
3.2.1 Inhibiting NTC assembly by small compounds
In a first approach, virtual high throughput screening (vHTS) was done in cooperation
with Jens Peter von Kries’ group at the Institute for Molecular Pharmacology (FMP),
Berlin. Docking was done using Surflex-Dock (http://tripos.com). The keyorganics
small compound database version of November 2007 was used as small compound input
(www.keyorganics.co.uk). It consists of approximately 40,000 small compounds. CSL
was used as target protein, the reasoning being, that a small compound binding to CSL
would possibly inhibit binding of NIC and MAML proteins to CSL. As structural basis
for the docking, the crystal structure of the NTC reported by Nam et al. [97] was used
(PDB accession code: 2f8x, resolution= 3.25Å, see figure 3.24).
To prepare the structure for virtual docking, NIC1, MAML1 and DNA structural data
was omitted. Initially, we identified 10 compounds with high Surflex-Dock scorings that
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Figure 3.24: Crystal structure of the NTC, PDB code 2f8x
Crystal Structure of the NTC bound to DNA. Blue: DNA; green: CSL; yellow: Ankyrin repeat
domain of NIC1; red: MAML1 amino acids 13-74. As repressive transcription factor, CSL stays bound
to DNA at according CSL binding sites. Upon NOTCH1 receptor cleavage (S2 and S3 steps), NIC1
translocates to the nucleus, binds to CSL, thereby forming a dual binding interface to which
co-activators of the Mastermind-like family may bind to form the transcriptionally active NTC.
Crystal structure data was downloaded from www.pdb.org and rendered using the UCSF Chimera
framework.
75
3 Results
at the same time bound to CSL regions that represent the surface to which NIC or MAML
proteins bind. The compounds have the following keyorganics accession numbers: 6M-
003, 10B-35, 10B-049, 10E-23, 12P-818, 12R-0816, 12R-1182, 3K-521S, 3R-0688, 3R-
0256. As exemplary result of the vHTS docking, the docked position of compound
6M-003 is shown in figure 3.25.
These compounds were then screened in a first functional screening in HEK293 cells
transfected with the NOTCH-reporter construct described above, the control luciferase
and the NIC1 construct to turn on NOTCH activity. Two compounds significantly
reduced reporter activity at concentrations of 100µM in comparison to DMSO treated
control samples (for the complete table of results please see appendix D).
Further reporter assays were done with these two compounds in varying concentrations
with the conclusion that at concentrations of 100µM both compounds reduce reporter
activity to 41% (6M-003) or 51% (12R-0816) of control activity (see table 3.5). At
this point functionality of these compounds seemed promising, additional substantia-
tion of this finding was done using proliferation assays of two cell lines with constitutive
NOTCH1 signaling (SUP-T1 and ALL-SIL [145, 130]) and one control cell lines which
does not show NOTCH1 signaling activity (Reh). Proliferation assays were performed
at differing concentrations of 6M-003 and 12R0816 (1µM, 35µM, 65µM, 100µM) and
DMSO as control (see figure 3.26). All cell lines tested had significantly reduced prolifer-
ation at 100µM of either compound. This may be interpreted as the compounds having
unspecific effects at such concentrations. Nevertheless, cell line ALL-SIL also showed
reduced proliferation at 35µM and 65µM concentrations of 6M-003. It was therefore
decided, to test and measure whether binding of these compounds to CSL would occur.
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Figure 3.25: Result of 6M-003 docking to CSL
Result of the Surflex-Dock based 6M-003 docking to CSL. Blue: CSL; turquoise: Ankyrin repeat
domain of NIC1; green: MAML1. 6M-003 is presented as centrally positioned stick-model.
3.2.2 Establishing purification of human CSL
To this end the sequence for human CSL spanning amino acids 9-435 were cloned into
pSKB2LNB with a N-terminal His-tag and a PreScission-protease-site. Protein expres-
sion was induced by addition of 100µM IPTG and was grown over night at 18°C. Protein
was then purified successively using Ni-NTA His-Tag purification, cutting of the tag with
PreScission-protease and subsequent final purification using size exclusion chromatogra-
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compound 6M-003 12R-0816
concentration 100µM 65µM 35µM 1µM 10/00 DMSO 100µM 65µM 35µM 1µM
luciferase ratio 0.522 0.588 0.627 1.286 1.385 0.718 0.830 1.106 1.434
standard devi-
ation
0.056 0.058 0.039 0.117 0.100 0.066 0.063 0.105 0.107
Table 3.5: NOTCH-reporter inhibition by small compounds
Dual luciferase NOTCH reporter assay was used to determine impact of compounds 6M-003 and
12R-0816 on NOTCH reporter activity in HEK293 cells. At a concentration of 100µM, both
compounds reduced reporter activity by ≈50%.
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Figure 3.26: Impact of 6M-003 and 12R-0816 on the proliferation of various cell lines
To assess impact of the two small compounds 6M-003 (a) and 12R-0816 (b) on proliferation,
[3H]-thymidine incorporation was measured in cell lines dependent on NOTCH signaling (SUPT1 and
ALL-SIL [145, 130]) and the cell line Reh, which is not known to be NOTCH dependent.
[3H]-thymidine incorporation was measured 120 hours after adding the compounds at various
concentrations or DMSO at 10/00 final concentration. [3H]-thymidine was added 96 hours after assay
start. Error bars denote standard deviation.
phy (see figure 3.27(a)). Analysis of the purified CSL on SDS-PAGE is shown in figure
3.27(b). Protein was also extracted from the gel and analyzed using mass spectrometry
to verify that the band in question is CSL. Apart from various E. coli proteins that
were detected, human CSL was identified with a MASCOT match score of 744 (please
see appendix E for a MASCOT report summary). To measure binding affinity of the
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compounds to CSL, Isothermal Titration Calorimetry (ITC) was used. No saturation
of a presumed binding activity was measurable, it was thus assumed, that either com-
pound does not specifically bind to CSL (see appendix F). Biological effects as seen in
the NOTCH1 reporter assays therefore have to be unspecific as well, both compounds
are therefore not usable for specific inhibition of NTC assembly.
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Figure 3.27: Purification of human CSL
Human CSL was purified using His-tag based affinity chromatography, followed by a polishing step
using size exclusion chromatography on a Sephadex G-200 column (a). (b) shows presence and purity
of recombinant CSL during various steps of the purification. LMW: low molecular weight marker; FT
Ni-NTA, flow through of the affinity column, note that only little CSL is seen in this fraction; w1:
wash 1; w2: wash 2; Elu1: 1st elution after precision protease cleavage on the affinity column; Elu2:
2nd elution of affinity column using 300mM imidazol, note, that most CSL is already eluted in Elu1;
Fractions #37-#43 correspond to the big elution peak in (a). Most CSL is found in fractions #38-#40.
3.2.3 Alternative targeting of the NTC
Usage of the small compounds 6M-003 and 12R-0816 to inhibit stable complex formation
of the NOTCH transcriptional complex could not be proven to work in a NOTCH specific
manner. It can not be ruled out, that more sophisticated methods of measuring binding
energies with for example all NTC components plus the compounds could prove to
be successful in terms of specific compound-NTC binding. Yet, in regard to available
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technical expertise and time-management this would have been beyond the scope of this
study.
Hence, a different strategy was developed. Based on the knowledge, that the truncated
version of MAML1 comprising amino acids 13 to 74 (DnMAML1), is a potent inhibitor
of NOTCH signaling, it was reasoned, that this might be a lead-peptide for developing a
potent NOTCH inhibitor. This peptide is still too long for scaled up chemical synthesis,
which would be needed as technical prerequisite for any potential drug. Additionally,
the smaller the peptide, the better its behavior in terms of bioavailability and the ratio
of cytoplasmatic to nuclear localization [146, 147, 148]. It was thus reasoned, that even
more truncated versions of this peptide would have to be designed and tested in order
to endorse or deny the possibility of such a peptide drug. Caveats of this approach
are the uncertainty of whether any synthesized peptide will subject to form the alpha-
helix that is inherent to the complete MAML1 protein by self-folding as soon as it is
within the cell. To circumvent this potential problem and in order to visually monitor
expression, it was decided to first design peptide-GFP fusion constructs for expression
directly within mammalian cells, thus producing correctly folded peptide-alpha-helix-
GFP fusion proteins. For the design of the peptide sequences to be used, the binding
interface as presented by the crystal structure of the NTC was screened for possible
charge-based interactions and hydrogen bonds. This screen and a recent publication
using mutational analysis of the MAML1 protein led to the identification of MAML1
amino acids R22, R25, R26, C30, R31 and H34 being the energetically most important
residues in terms of binding enthalpy [149, 97, 150, 151]. Moreover, it has been shown,
that DnMAML1 competitively inhibits binding of all three members of the mastermind-
like family, as the residues important for complex formation are highly conserved among
the human MAML proteins [96, 100]. Using this information lead to the design of two
peptide-GFP constructs (see figure 3.28), where one comprises MAML1 amino acids 13
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to 50 (hereafter referred to as DnMAML1 AA 13-50) and the other spans MAML1 amino
acids 19 to 36 (hereafter referred to as DnMAML1 AA 19-36). Both were N-terminally
fused to GFP for further functional analysis in appropriate in vitro systems.
MAML1 AA 1-1016
DnMAML1 AA 13-74
DnMAML1 AA 13-50
DnMAML1 AA 19-35
BD TAD1 TAD2
Figure 3.28: Design rationale of NTC inhibiting peptide constructs
Based on crystal structure information and mutation studies, two shortened MAML1 based peptide
constructs were designed for further testing of their potential to specifically inhibit NOTCH signaling.
The domains of native MAML1 (AA 1-1016) are shown, all inhibitory peptides are positioned in the
binding domain (BD) that mediates binding to NIC and CSL. TAD: trans activation domain.
3.2.4 Short MAML1 based GFP-fusion constructs effectively inhibit
induction of a NOTCH reporter assay
To test the various DnMAML1-GFP fusion constructs, the cell line SUP-T1 (with in-
herent constitutive NOTCH signaling) was transfected with the NOTCH1-reporter con-
struct, the according control construct (both described in section 3.1.12) and either of
the truncated versions of MAML1. Using the classical construct (DnMAML1 AA 13-74)
the NOTCH activation dropped to 9.6% of the basal SUP-T1 level, using DnMAML1
AA 13-50 the level was reduced to 30.5% and using DnMAML1 AA 19-36 reduced basal
levels of NOTCH reporter activation down to 54.0%. We concluded, that all three con-
structs significantly reduce reporter activation in this in vitro system and subsequently
wanted to further substantiate this finding by additional functional studies.
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Figure 3.29: Inhibition of a NOTCH-reporter system by small peptide constructs
The T-ALL cell line SUP-T1 was used for measuring NOTCH1 reporter activity after transfection
with the NOTCH1-reporter construct (Hes1-pGL2) or its respective control (pEGFP) and the various
short, MAML1 based, GFP-fused peptide constructs. Cells were lysed and luciferase ratios measured
48 hours after transfection. Error bars denote standard deviation. Western blot analyses of whole cell
lysates were done for controlling the expression of the various constructs. Note, that all pEGFP fusion
constructs possess alternative start sites for expression of GFP only. This might explain why — e.g.
in case of the DnMAML1-pEGFP AA 13-74 — apart from expression of the peptide-GFP construct,
additional expression of a GFP-sized protein is detectable. *: p<0.001
3.2.5 Monitoring of the inhibition of NTC assembly using EMSA
To assess NTC assembly, electrophoretic mobility shift assays (EMSA) were performed
with the consensus HES1 binding site as probe (described in [134]). Three core compo-
nents of the NTC (NIC1, CSL, MAML1) were ectopically expressed in HEK293 cells.
Each truncated version of MAML1 was then tested to see possible out-competition
of native NTC formation. As seen in figure 3.30, ectopic expression of NIC1, CSL
and MAML1 resulted in stable formation of the transcriptionally active high molecu-
lar weight NTC. Adding DnMAML1 AA 13-74 results in almost total out-competition
(no high molecular weight NTC is detectable by EMSA) of native, full length MAML1.
Subsequently a NTC with a substantially lower molecular weight is formed and visible
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by EMSA analysis. Using either of the shorter constructs (DnMAML1 AA 13-50/AA
19-36) also resulted in reduced detection of the high molecular weight NTC which is
vastly reduced in case of DnMAML1 AA 13-50 and well reduced when using DnMAML1
AA 19-36. Notably, no lower molecular weight complex is detectable with these two
shortest constructs, presumably because formed complexes are highly unstable, thus
being undetectable by EMSA analysis.
At that time, a study from Moellering et al. was published [145], that also focused
on the development of short, MAML1 based competitive peptide inhibitor constructs.
In this work they found, that indeed amino acids 21-36 of MAML1 suffice to construct
a potent competitive peptide inhibitor, that can disrupt native NTC formation. As a
chemical modification, Moellering et al. introduced an olefin bridge (a process they called
peptide-stapling) that significantly enhances α-helical folding of this peptide sequence -
the conformation needed for binding of MAML proteins or their derivatives to the dual
binding interface of NIC and CSL. In a broad in vitro and in vivo study, these peptide
constructs were shown to inhibit NOTCH signaling in a highly specific manner [145].
Therefore, our findings are in good accordance with their results.
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Figure 3.30: Peptide inhibition of NTC assembly
HEK293 cells were transfected with various constructs to monitor assembly of the normal NTC and
the inhibition of this assembly by usage of differently sized MAML1 based peptide constructs. Cells
were harvested 48 hours after transfection and used for preparation of nuclear extracts. These were
then analyzed using a Hes1-probe EMSA. Expression of all constructs was monitored using western
blotting, where PARP1 was used as control. Normal NTC assembly is only seen, when the four
essential NTC components DNA, CSL, NIC1 and (in this case) MAML1 are present in sufficient
amounts (see lane 6, marked with *). This complex assembly is inhibited by the presence of short,
MAML1 based peptide constructs, in case of the classical DnMAML1 AA 13-74 this will result in the
formation of a stable, transcriptionally inactive NTC (see lane 7, marked with **). Transfection with
the two constructs designed in this study also significantly inhibits NTC complex assembly (see lanes
8 and 9). n.s.: unspecific band.
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3.2.6 Short summary and conclusions, part II
Below, the most important aspects and conclusions of part II of this work are listed:
• vHTS of≈40,000 small compounds from the Keyorganics small compound database
led to the identification of 10 compounds that potentially may bind to human CSL
in a specific manner.
• Two of these compounds (6M-003 and 12R-0816) significantly inhibited NOTCH
transcriptional activation in a NOTCH1-reporter assay. They also inhibited pro-
liferation of NOTCH1-signaling dependent cell lines (SUP-T1 and ALL-SIL). Yet,
this is also the case for a cell line which presumably is not dependent on NOTCH
signaling (Reh).
• Binding studies using ITC did not show specific binding of either compound to hu-
man CSL. However, it can not be ruled out that NTC assembly might be disrupted
by these compounds.
• Short, MAML1 based peptide-GFP fusion constructs significantly inhibit NOTCH
transcriptional activation in a NOTCH-reporter assay and NTC assembly in vitro.
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4.1 Identification of a new NOTCH-deregulating
mechanism through analyses of high-dimensional
data
Analyzing the cHL NOTCH signature
Using the analyses of high-dimensional microarray data, this work shows, that cHL is
characterized by a distinct and global NOTCH signature which separates this malignancy
clearly from other B cell associated malignancies. This NOTCH signature shows, that
various genes involved in this pathway are deregulated in HRS cell lines and also in cHL
primary material when extending the analyses with the dataset GSE12453. It thereby
confirms earlier studies [55, 56, 74, 75] and extends the cHL-context view on NOTCH
signaling from relatively view NOTCH core components and target genes to a NOTCH-
global perspective. Considering the significant number of deregulated, overlapping genes
comparing primary cHL samples and HRS cell lines (globally and for NOTCH associated
genes), these results also imply that HRS cell lines are still very similar to cHL primary
cases and thus are a well suited experimental system for cHL research.
The NOTCH gene set for this study was compiled with the aim to provide a systemic
understanding and specification of the NOTCH signaling pathway. Research on the
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NOTCH signaling pathway is in the focus of many scientists and in turn, much data on
this pathway is being published constantly. Hence, the NOTCH gene set designed in this
study will have to be recompiled from time to time, as more evidence about NOTCH
associated genes becomes available and existing information is refined or rejected due to
new studies.
Though making systemic understanding of NOTCH signaling more readily conceiv-
able, our NOTCH gene set is not by itself giving any information about the relations
and inter-dynamics of its components. Therefore — as future prospect — the members
of this set should be used as basis for inferring directed NOTCH regulatory networks.
This would be a major step in terms of gaining insights into the directionality and con-
nectivity of NOTCH associated genes with each other. Of course this may be extended
to networks that are in close proximity to NOTCH signaling. Also this set should be
used when trying to confirm or reject the hypothesis of deregulated NOTCH signaling
in other malignancies and may prove to be a helpful tool in this regard.
From analyzing the cHL NOTCH signature, we detected the high-level expression of
the essential NOTCH co–activator MAML2, which is inappropriate when comparing
HRS cell lines to non-Hodgkin cell lines. This finding was extended and confirmed for
the comparison of normal, tonsillar B cells with primary material from cHL samples,
and was extended to other B cell associated malignancies such as B-ALL and MCL.
This should result in focused research elucidating the role and possibility of MAML2
mediated and deregulated NOTCH signaling in these malignancies, at the same time
using gained information for finding of therapeutical approaches.
Our data moreover imply, that in terms of NOTCH target gene regulation (HES7
and HEY1 ) and NOTCH dependent proliferation, high-level MAML2 expression may
be rate limiting for cHL context-specific NOTCH signaling.
To confirm this hypothesis in future studies, the presence and the quantity ratio (to
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the other MAML members) of MAML2 as part of an endogenous, native cHL NTC
needs to be demonstrated. Yet, so far, no published study could provide data on an
endogenous NTC, all studies of the NTC use recombinant or ectopically expressed NTC
component proteins (see for example [96, 134, 150]). The difficulty in detection and the
analysis of an endogenous NTC is most probably due to the fact, that it is present as a
1.5MDa complex (the NTC recruits various other proteins of the basic transcriptional
machinery, see above) [152]. This complex size results in various technical difficulties.
Jeffries et al. [152] used a sophisticated set up of sub-cellular fractionation followed by
SEC for detection of NTC components and were able to co-elute ectopically expressed
NIC1 with native CSL and MAML proteins. This technical approach could be adapted
and enhanced for future studies aiming to dissect the characteristics of native NTC
complexes in cHL.
Pointing out a discrepancy
In 2005, Zweidler-McKay et al. [76] showed that transduction of the HRS cell line L428
with a NIC1 and GFP expressing viral construct resulted in decrease of the percentage
of GFP+ cells over time. This was interpreted as growth arrest, and — using the
same experimental approach — was extended to other B cell associated malignancies.
Contrarily, our findings indicate that NOTCH signaling is essential for HRS cell line
proliferation. It may be speculated, that the experimental approach chosen by Zweidler-
McKay et al. is too artificial and hard to control in terms of viral integration sites and
subsequent, anti-proliferative effects. Additionally, the measurement of the percentage of
GFP+ cells as indicator for proliferation is a far more indirect parameter in comparison
to e.g. 3H-thymidine incorporation, which could hamper the interpretability of results.
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What to consider, when analyzing the NOTCH signaling system
Adding to the known mechanisms which lead to deregulation of the NOTCH signaling
pathway, namely mutations within NOTCH receptors and mutations of ubiquitin ligases
that mediate the turnover of the NTC, we showed that high-level expression of NOTCH
co-activators will also deregulate NOTCH signaling in a pathological manner (figure
4.1). This is also the case in cells where the obvious levels of NIC within the nucleus
are relatively low (e.g. L428 and L1236) but in conjunction with high concentrations of
MAML2 protein still suffice to deregulate NOTCH signaling. In opposite, high levels of
NIC still do not have to result in aberrant and NOTCH-dependent proliferation of cells
(e.g. in the case of BJAB cells). This points out that, when looking for deregulated
NOTCH signaling in different disease entities, it is not sufficient to just assess levels of
NOTCH receptor expression (as for example done in [56]), but it is rather essential to
look at all activating core components — cleaved NOTCH and the Mastermind-like co-
activators. Whenever possible, even all components associated with NOTCH signaling
should be looked at quantitatively in order to get a global picture of the state of NOTCH
signaling in a cellular system.
Not only MAML2, but regulation of various other genes may be the result of or
influence cHL specific NOTCH signaling
Recent studies have shown a limited number of NOTCH associated genes to be dereg-
ulated in cHL [55, 56, 74, 75]. The deregulation of many of these genes (see above
and appendix C) could be confirmed and was extended to a NOTCH-systemic analy-
sis which has shown a significant deregulation of the NOTCH signaling system. As a
most interesting gene found to be NOTCH1 regulated in HRS cell lines [75], the T-cell
transcription factor GATA3 was also one of the most significant hits when analyzing
the different datasets described above (see table 3.3 and also appendix C). Another
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gene found in our statistical analyses in accordance with previously published data (see
[55, 56]) was NOTCH2. Due to the unavailability of a specific antibody detecting the
cleavage product of NOTCH2 (NIC2) we could unfortunately not analyze, whether this
receptor may also contribute to a super-induction of NOTCH signaling in HRS cell lines.
Future studies will have to elucidate this possibility.
Interestingly the cHL specific deregulation of the basic helix-loop-helix transcription
(bHLH) factor HES7 which this study shows to be due to MAML2 deregulation may also
result in another mechanism deregulating E2A activity. The deregulation of E2A in cHL
is a commonly known defect and various mechanisms have been described that contribute
to this deregulation. Mathas et al. [48] for example have shown, that high levels of
ABF1 and ID2 inhibit E2A dependent transcription which ultimately contributes to the
cHL-typic loss of the B cell phenotype. In a recent study HES7 — being a repressive
transcription factor — was shown to inhibit E2A dependent transcription [153]. Future
research will have to focus on this being another potential mechanism of inhibited E2A
dependent transcription in the specific context of classical Hodgkin lymphoma.
One has to mention, that the deregulation of JAG2 was not detected by gene expres-
sion profiling, presumably because biological group-variance is too large. As result, the
applied statistical tests did not deem this gene to be significantly deregulated. One has
to conclude, that the analyses of high-dimensional data from disease entities is always
to some degree dependent on genetic homogeneity. If possible, gene expression profiling
should therefore always be completed with complementary array-qPCR for the gene sets
of interest.
Many other genes with a putatively very important role in cHL-specific NOTCH sig-
naling (see table 3.3) will have to be functionally analyzed in regard to their contribution
to NOTCH deregulation in future studies.
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Figure 4.1: A new NOTCH-deregulation mechanism
In diseases associated with deregulated NOTCH signaling (e.g. T-ALL), two major mechanisms have
been elucidated, that will result in pathological deregulation of the pathway. First, mutations of the
NOTCH receptors, especially of the HD and PEST domains will lead to facilitated cleavage or
reduced turn-over, respectively. Second, mutation or deletion of ubiquitin ligases involved in turn-over
of the NOTCH transcriptional complex will result in increased half-life and hence, sustained
transcriptional activity of the complex.
This study shows, that — in case of cHL — high-level expression of MAML2 also provides a
mechanism for deregulating the NOTCH pathway significantly. This points out the importance to
therapeutically target this complex at its assembly stage rather than upstream of the signaling
cascade.
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Cell-autonomous NOTCH activation in cHL
In this study we show evidence, that NOTCH1 signaling is not only super-induced
by high-level MAML2 expression but also activated in a cell-autonomous fashion. In
HRS cell lines, additionally to the activation through the cHL microenvironment as
suggested by Jundt et al. [56] it confirms and extends studies that already suggested
this cell-autonomous activation (by showing target gene regulation in HRS cell lines
after NOTCH1 knockdown, see [74, 75]). As most important proof for this hypothesis,
we have shown the constitutive presence of NIC1 in the nucleus of HRS cell lines.
The cleavage of the NOTCH1 receptor to NIC1 seen in all HRS cell lines at low to
high levels may be due to the high-level expression of JAG2 in various HRS cell lines
and the high-level expression of JAG1 in L591. The contribution of these two ligands to
activated NOTCH signaling will have to be demonstrated in future studies, especially
taking into account a recently published mathematical model trying to integrate cis
and trans NOTCH/ligand interactions to a specific intracellular read-out [112]. This
study focused on NOTCH1/DLL1 interactions, and indicates that cis-NOTCH/ligand
interactions rather inhibit NTC activation, whereas trans-activations will activate NTC
dependent transcription, a finding that was partly extended to JAG1 by Cordle et al.
[154].
Mastermind-like proteins emerging as master regulators
What still remains to be elucidated, is the role of cross-effects of different MAML pro-
teins and their individual specific effects on NOTCH signaling and the fine-tuning of
NOTCH signaling. It is interesting, that MAML1 is expressed at similar levels in all
cell lines tested and MAML3 is only present at robust levels in some of the cell lines
tested. Yet, inhibiting the high-level expression of MAML2 is already sufficient to block
NOTCH mediated proliferation and expression of certain target genes in cHL. These
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results, though indicating that MAML1 and MAML3 mediated NOTCH signaling is
pathologically less important in cHL, will have to be further substantiated by functional
experiments, especially when one wants to elucidate their potential role in other B cell
associated malignancies.
More generally, a study by Kitagawa et al. reported on the potentially important role
of MAML1 analyzing MAML1−/− mice [101]. These mice show severe growth retardation
and early death at day 14 of the postnatal period. Seemingly, MAML1 deficiency also
results in impaired development of early thymocytes and also shows clear inhibition of the
development of marginal zone B cells [92]. This emphasizes the importance of MAML1
in the development the hematopoetic compartment, whether this is purely the result of
MAML1 mediated NOTCH signaling is unknown and will have to be shown in future
studies. The result, that HES1 levels in MAML1−/− mice were not significantly reduced
in comparison to MAML1+/+ mice points into the direction, that there may be other
mechanisms affected by MAML1. Also, inhibition of NOTCH signaling using dominant
negative mutants of either MAML1, MAML2 or MAML3 in murine hematopoetic stem
cells resulted in early inhibition of T-cell development and the appearance of intrathymic
B cells [100]. This implies that either MAML member may be of vital importance for
Notch-mediated cell fate decisions.
Adding to the complexity, more and more studies extend the picture of the MAML1
co-activator to other pathways then NOTCH signaling. Regulation of NF-κB signaling
through Maml1 regulation of p65 and IκBα has recently been shown in vitro, furthermore
MEF2C regulation and even p53 activity seem to be in part to be mediated through
the MAML1 protein [103, 155, 156]. In addition, the activity of the MAML1 protein
seems also to be regulated through certain mechanisms. Lately one study revealed,
that SUMOilation may prove to be an important factor determining in how far MAML
proteins are capable of activating e.g. NOTCH signaling [99].
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Unfortunately, little to nothing is known about the specific role of MAML2 and MAML3
in the differentiation process of hematopoiesis and about their role in differentiated
tissues as most studies focus on MAML1. However, studies with ectopic expression of the
MAML2 and MAML3 proteins show that they do have a great potential in activating the
NOTCH signaling pathway significantly [95, 96]. Other studies show that translocation
of the MAML2 gene and its fusion to genes such as MECTC1 and TORC1 will lead to
oncogenic events [104, 105] and thus imply that MAML2 has the potential to activate
various intracellular signaling pathways. Our study additionally provides data that
clearly speaks in favor for an important role of MAML2 in — at least — the lymphocytic
context. Nevertheless, much work will have to be done in order to unravel the functions
of these proteins by using for example adequate mouse models.
Putting NOTCH signaling in a wider context
A recent study has shown, that the up-regulation of the T-cell transcription factor
GATA3 in HRS cell lines is caused by two major signaling pathways — NOTCH and
NF-κB [75]. More generally, the fact that p65 and CSL DNA consensus-binding sites
show strong similarity [157, 158] also point out, that both pathways may compete for
regulation of the same target genes and will make it necessary to develop a systemic
view on both pathways and their possible interplay in different cellular decision-making
processes. This systemic view on NOTCH and NF-κB signaling ultimately will have to
be extended to a holistic description of cHL as disease system, putting each pathway-
subnetwork in its place and in relation to other pathway-subnetworks.
Overall, this newly unraveled, MAML2 dependent deregulation mechanism of NOTCH
signaling adds to the complexity of this pathway. As this deregulation takes place at the
DNA-protein level and in this respect the core-site of regulation of NOTCH mediated
transcriptional activation it is of utmost importance to target NOTCH signaling at this
level.
94
4 Discussion
4.1.1 Systemic disease models for cHL — a perspective
Various major pathways of the hematopoetic system have been shown to be severely
deregulated in classical Hodgkin lymphoma and there is now evidence that addition-
ally epigenetic dysregulation plays an important role in the pathogenesis of this disease
[46, 57]. The gene expression analysis we performed showed ≈4700 features to be signifi-
cantly deregulated in HRS cell lines when compared to non-Hodgkin cell lines. One may
easily conclude, that it will still take decades to put all these results into perspective,
especially when each and every possible hypothesis will have to be validated experimen-
tally. Rather than looking at every factor one at a time it will be of great importance
to use available datasets to describe cHL in a systemic fashion. In order to do so,
it will not be sufficient to use standard statistical procedures such as cluster analysis,
PCA or GSEA that are being used currently to systematically describe disease entities
[24, 57, 159]. While these kinds of analyses set a good basis for hypothesis generation,
they lack the capability of connecting different pieces of information. This caveat can
be accounted for by generation of — in case of cHL — complete B cell network models.
Recent publications have shown promising results in this respect [160, 161, 162] yet in
case of Bayesian and mutual-information based network models, there is still much po-
tential of improvement in terms of for example run-time complexity, the possibilities to
integrate different data types and to account for technical variance in between different
datasets. Nevertheless, inference of near-complete genetic interaction and regulatory
networks enables researchers to identify and select functional clusters that are most
promising in disrupting the cellular interaction network of a specified disease. This will
be essential as to find new therapeutic approaches possibly circumventing late toxicities
due to deployment of traditional chemotherapy and radio therapy that are a common
feature of traditional cHL treatment. According to network theory of biological net-
works one would assume, that there are only relatively few major hub-proteins within
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the network and that these important proteins have a shallow interaction architecture
[163]. Identifying them will provide molecules, that should be targeted therapeutically.
In regard to this work, we have shown how computer-aided analyses of data from high-
throughput-experiments helps to understand disease-specific pathway regulation at sys-
temic/holistic level. Extension of these analyses to even larger datasets will at some
point enable researchers to completely infer a systemic cHL disease model.
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4.2 Strategies to target NTC assembly as therapeutic
approach
Using vHTS for small compound identification
Virtual High Throughput Screens and computer aided compound design are basically
free of charge tools to predict compound binding to proteins. This technique has suc-
cessfully been applied in a growing number of studies [164, 165]. Different docking
algorithms have been developed and many of them have proven useful in some studies
[166]. Success though is so far mostly limited to enzymes and receptor-proteins. Both
classes of molecules normally contain binding grooves for native ligands. These grooves
usually have special biophysical and structural characteristics predisposing them for sta-
ble binding of compounds with complimentary characteristics. In opposite, successful
small compound binding to proteins that do not display such binding grooves seems par-
ticularly hard to accomplish. The NOTCH transcriptional complex consists of proteins,
that mainly present flat surfaces rather then cavities. Moreover the available crystal
structure of the NTC has only a low resolution (3.25Å, see [97]). Taking into account
the cost-effectiveness and rapidity of vHTS, we decided to use this technique for a screen
which identified a limited number of high-score hits. Functional screens for the NTC
transcriptional activation were already established, however are seemingly prone to mea-
suring effects that are not singularly due to targeting of NOTCH signaling. Though we
identified two compounds that had shown activity in our two functional assays, a sub-
sequent measurement of binding energy had shown that there presumably is no specific
binding of either compound to CSL. This shows the caveats of the vHTS approach and
the usage of small compounds in general — the docking technique relies on structural
information, which in case of X-ray crystallography may not represent what is found in
solution within a living cell, does not account for structural dynamics of the protein and
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moreover there will be quality issues in terms of structure resolution. As NMR-based
in-solution structures become more and more available even for large proteins [167],
these structural informations may prove to be of higher quality and will presumably get
closer to the structure one expects under the physiological conditions of a cell and thus
be more suitable for vHTS screens. If there are functional and specific screens available
that can measure effects on a certain protein, vHTS nevertheless is a good option in
order to identify potential small molecule inhibitors. Of course the potential toxicity
of these compounds may then present a further problem when going from bioanalytical
assays to cellular or mouse models.
Developing peptide inhibitors
Targeting a certain protein or protein complex always should be preceded by a thorough
investigation of all available information with special emphasis on resolved structures,
binding studies and mutational studies. Doing this for the NOTCH transcriptional
complex we established the hypothesis, that a short alpha-helical MAML1 derivative
could be the basis for the design of a potent competitive inhibitor of NOTCH tran-
scriptional complex formation. MAML1 being completely alpha helical predestines this
simple structured protein for being the basis of producing chemically synthesized pep-
tides, that depending on their size and amino acid composition would then freely diffuse
across the cell and nuclear membranes [145, 146, 147, 148]. Other elegant ways such as
fusing a small effector peptide to HIV-TAT [168, 169] have been described and make
promising steps into the direction of the application of small peptide drugs in mouse
models or even humans. Polo et al. for example were successful in using a TAT-fused
BCL6-binding peptide which effectively induced apoptosis in BCL6-positive lymphoma
cells [169]. This stresses the feasibility of this kind of therapeutic approach.
In this study we have shown, that indeed a very short MAML1 derived peptide se-
quence contains the core motif necessary for construction of a potent competitive in-
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hibitor of NOTCH transcriptional complex formation.
At the same time this was found by Moellering et al. who described — in accor-
dance with our results — that MAML1 amino acids 21-36 are sufficient for construction
of an inhibitory peptide disrupting NTC assembly [145]. They moreover have shown,
that the unmodified, chemically synthesized peptide MAML1 amino acids 21-36 exhibits
only 23% alpha-helicity. These findings point out that, when designing a peptide drug,
consideration of the desired secondary or tertiary structure is of utmost importance.
Moellering et al. circumvented this problem by stabalizing alpha-helical folding through
so-called ’peptide-stapeling’ where an olefin-bridge is introduced between I27 and H31
(i.e. between position i and i+4 as to mimic alpha-helix-like hydrogen-bond formation).
This resulted in 94% alpha-helicity. In subsequent experiments, Moellering et al. thor-
oughly characterised their peptides and different derivatives and have shown that indeed
NOTCH transcriptional activation is inhibited in vitro and in vivo. Usage of these pep-
tides in different NOTCH dependent human T-ALL cell lines resulted in induction of
apoptosis. Additionally, lethally irradiated mice were reconstituted with haematopoetic
stem cells, which were modified to have NOTCH signaling constitutively activated and
then treated with the peptide inhibitor or the respective control. The subsequent tu-
mor burden was significantly lower in mice treated with the peptide. The next step in
advancing this promising drug template will be the thorough characterization of pos-
sible toxicity and the stability of the peptide in vivo. Also, ways how to administer
the peptide to potential patients in an effective manner will have to be explored. If all
this proves to be at acceptable levels, clinical trials will have to show usability of this
NOTCH inhibitory peptide in the therapy of NOTCH associated diseases.
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4.2.1 On a promising way — specific inhibition of transcription
factor complexes
The results of part II of this work show that generally protein-complex assembly may
be inhibited if some binding event may be outcompeted by usage of truncated, binding-
capable but otherwise non-functional derivatives of one of the complex-composing pro-
teins. However, applicability is always reduced to cases, where derivatives are very small
in terms of molecular weight and thus are readily synthesized by chemical synthesis. At
the same time it has to be guaranteed, that structural and stability requirements for the
peptide are met. Size also matters in terms of transfer of the peptide from its location
of application to the target. As additional caveat, inhibition of any process in healthy
tissue will lead to undesirable counter effects, making it necessary to develop applica-
tion and targeting strategies for most specific deployment of the peptide drug. Before
deciding whether to target a disease-associated complex or single molecule with a small
compound or a peptide inhibitor, a thorough biological and biophysical characterization
should precede the decision. Especially in cases where the molecule of interest con-
tains hydrophobic pockets or other surface characteristics suitable for small compound
binding, this kind of approach should be preferred (e.g. this is often the case for kinases).
In summary we have shown that the development of NOTCH signaling pathway specific
peptide inhibitors is a promising way and tool to create and design drugs that most
specifically inhibit this pathway at a crucial step, namely the NTC assembly. Various
NOTCH associated malignancies (even those showing GSI resistance, see [145]) may be
treatable using this peptide inhibitor. In case of cHL this might become a new way
circumventing the devastating effects of traditional chemo- and radio-therapy and thus
improve quality of life of patients substantially.
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Below, all genes found in either database to be associated with the NOTCH signaling
pathway are listed.
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Affymetrix ID Gene Name BioGRID1 KEGG2 NetAffx3 PUBMED ID4
209743_s_at; 217094_s_at;
217094_s_at
ATROPHIN-1 INTERACTING PRO-
TEIN 4
x
201502_s_at NUCLEAR FACTOR OF KAPPA
LIGHT POLYPEPTIDE GENE EN-
HANCER IN B-CELLS INHIBITOR,
ALPHA
x
202360_at MASTERMIND-LIKE 1
(DROSOPHILA)
x
213494_s_at; 224711_at;
200047_s_at; 201901_s_at;
201902_s_at
YY1 TRANSCRIPTION FACTOR x
32137_at; 209784_s_at JAGGED 2 x
241378_at; 228261_at; 241541_at;
226644_at; 241377_s_at
MINDBOMB HOMOLOG 2
(DROSOPHILA)
15824097
221036_s_at ANTERIOR PHARYNX DEFEC-
TIVE 1 HOMOLOG B (C. ELE-
GANS)
x
213091_at; 207159_x_at CREB REGULATED TRANSCRIP-
TION COACTIVATOR 1
x
204863_s_at; 234967_at;
234474_x_at; 212196_at;
211000_s_at; 204864_s_at;
212195_at
INTERLEUKIN 6 SIGNAL TRANS-
DUCER (GP130, ONCOSTATIN M
RECEPTOR)
x
229540_at; 207785_s_at;
211974_x_at
RECOMBINING BINDING PRO-
TEIN SUPPRESSOR OF HAIRLESS
(DROSOPHILA)
x
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204153_s_at; 213783_at;
204152_s_at
MANIC FRINGE HOMOLOG
(DROSOPHILA)
12486116; 10935626
218512_at WD REPEAT DOMAIN 12 x
202064_s_at; 202062_s_at;
202061_s_at; 230265_at;
202063_s_at
SEL-1 SUPPRESSOR OF LIN-12-
LIKE (C. ELEGANS)
12553058
204849_at; 235694_at TRANSCRIPTION FACTOR-LIKE 5
(BASIC HELIX-LOOP-HELIX)
16990763
206480_at LEUKOTRIENE C4 SYNTHASE x
221315_s_at; 1566814_at;
1566816_at
FIBROBLAST GROWTH FACTOR
22
16990763
209200_at; 207968_s_at;
209199_s_at
MADS BOX TRANSCRIPTION EN-
HANCER FACTOR 2, POLYPEP-
TIDE C (MYOCYTE ENHANCER
FACTOR 2C)
10082551 ;16510869
207835_at; 201787_at; 202994_s_at;
207834_at; 202995_s_at
FIBULIN 1 16990763
218902_at; 223508_at NOTCH HOMOLOG 1,
TRANSLOCATION-ASSOCIATED
(DROSOPHILA)
x
206759_at; 206760_s_at FC FRAGMENT OF IGE, LOW
AFFINITY II, RECEPTOR FOR
(CD23A)
11986231
209151_x_at; 213732_at;
215260_s_at; 209152_s_at;
228052_x_at; 213811_x_at;
213730_x_at; 210776_x_at;
213731_s_at; 209153_s_at
TRANSCRIPTION FACTOR 3 (E2A
IMMUNOGLOBULIN ENHANCER
BINDING FACTORS E12/E47)
18449208 ; 18815281
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203867_s_at; 203866_at NOTCHLESS HOMOLOG 1
(DROSOPHILA)
x
208893_s_at; 208891_at;
208892_s_at;
DUAL SPECIFICITY PHOS-
PHATASE 6
16990763
206847_s_at HOMEOBOX A7 16990763
211269_s_at; 206341_at INTERLEUKIN 2 RECEPTOR, AL-
PHA
16612405
211148_s_at; 236034_at; 205572_at ANGIOPOIETIN 2 16990763
212611_at DELTEX 4 HOMOLOG
(DROSOPHILA)
x
225415_at DELTEX 3-LIKE (DROSOPHILA) x
235106_at; 235457_at MASTERMIND-LIKE 2
(DROSOPHILA)
x
209239_at NUCLEAR FACTOR OF KAPPA
LIGHT POLYPEPTIDE GENE EN-
HANCER IN B-CELLS 1 (P105)
x
215270_at; 228762_at LUNATIC FRINGE HOMOLOG
(DROSOPHILA)
16612405
202604_x_at; 214895_s_at ADAM METALLOPEPTIDASE DO-
MAIN 10
16612405
204501_at; 214321_at NEPHROBLASTOMA OVEREX-
PRESSED GENE
12050162
213260_at; 1553613_s_at FORKHEAD BOX C1 x
214722_at; 227067_x_at NOTCH HOMOLOG 2
(DROSOPHILA) N-TERMINAL
LIKE
14673143
209945_s_at; 1554417_s_at;
218389_s_at; 237327_at
GLYCOGEN SYNTHASE KINASE 3
BETA
x
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202284_s_at; 1555186_at CYCLIN-DEPENDENT KINASE IN-
HIBITOR 1A (P21, CIP1)
19091404
229195_at; 243387_at; 224476_s_at MESODERM POSTERIOR 1 HO-
MOLOG (MOUSE)
x
201465_s_at V-JUN SARCOMA VIRUS 17 ONCO-
GENE HOMOLOG (AVIAN)
14645224
215732_s_at DELTEX2 HOMOLOG
(DROSOPHILA)
x
226281_at DELTA-NOTCH-LIKE EGF
REPEAT-CONTAINING TRANS-
MEMBRANE
x
227678_at; 1554349_at XRCC6 BINDING PROTEIN 1 x
201996_s_at; 201997_s_at;
1556059_s_at;1556058_s_at
SPEN HOMOLOG, TRAN-
SCRIPTIONAL REGULATOR
(DROSOPHILA)
x
211252_x_at; 211837_s_at;
215492_x_at
PRE T-CELL ANTIGEN RECEP-
TOR ALPHA
16612405
218284_at; 205396_at; 205398_s_at SMAD, MOTHERS AGAINST DPP
HOMOLOG 3 (DROSOPHILA)
x
207538_at; 207539_s_at INTERLEUKIN 4 15137944
204262_s_at; 204261_s_at;
211373_s_at;
PRESENILIN 2 (ALZHEIMER DIS-
EASE 4)
16612405
209097_s_at; 209099_x_at;
216268_s_at; 209098_s_at;
231183_s_at
JAGGED 1 (ALAGILLE SYN-
DROME)
x
213147_at; 213150_at HOMEOBOX A10 16990763
224726_at; 224722_at; 236573_at;
224720_at; 224725_at; 1558645_at
MINDBOMB HOMOLOG 1
(DROSOPHILA)
x
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203237_s_at; 203238_s_at NOTCH HOMOLOG 3
(DROSOPHILA)
x
215205_x_at; 208888_s_at;
207760_s_at; 208889_s_at
NUCLEAR RECEPTOR CO-
REPRESSOR 2
x
215424_s_at; 201575_at SNW DOMAIN CONTAINING 1 x
207195_at CONTACTIN 6 x
230568_x_at; 219537_x_at;
229755_x_at; 222898_s_at;
DELTA-LIKE 3 (DROSOPHILA) x
212349_at; 210433_at; PROTEIN O-
FUCOSYLTRANSFERASE 1
x
203460_s_at; 207782_s_at;
238816_at; 1567440_at;
1567443_x_at; 226577_at;
1559206_at
PRESENILIN 1 (ALZHEIMER DIS-
EASE 3)
16612405
203845_at; 239585_at P300/CBP-ASSOCIATED FACTOR x
1559295_at; 235858_at; 202160_at;
211808_s_at; 237239_at
CREB BINDING PROTEIN
(RUBINSTEIN-TAYBI SYNDROME)
x
212377_s_at; 210756_s_at;
202445_s_at; 202443_x_at
NOTCH HOMOLOG 2
(DROSOPHILA)
x
224548_at HAIRY AND ENHANCER OF SPLIT
7 (DROSOPHILA)
x
208292_at BONE MORPHOGENETIC PRO-
TEIN 10
x
227347_x_at HAIRY AND ENHANCER OF SPLIT
4 (DROSOPHILA)
x
223525_at DELTA-LIKE 4 (DROSOPHILA) 16612405
227336_at DELTEX HOMOLOG 1
(DROSOPHILA)
16612405
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220662_s_at; 226828_s_at HAIRY/ENHANCER-OF-SPLIT RE-
LATED WITH YRPW MOTIF-LIKE
x
203394_s_at; 203395_s_at;
203393_at
HAIRY AND ENHANCER OF SPLIT
1, (DROSOPHILA)
x
209073_s_at; 236930_at;
207545_s_at; 230462_at
NUMB HOMOLOG (DROSOPHILA) x
221333_at; 221334_s_at; 224211_at FORKHEAD BOX P3 19267400
205247_at; 240786_at NOTCH HOMOLOG 4
(DROSOPHILA)
16612405
210948_s_at; 221558_s_at;
221557_s_at
LYMPHOID ENHANCER-BINDING
FACTOR 1
17585052
211370_s_at; 211371_at MITOGEN-ACTIVATED PROTEIN
KINASE KINASE 5
16990763
218751_s_at; 229419_at; 222729_at F-BOX AND WD-40 DOMAIN
PROTEIN 7 (ARCHIPELAGO
HOMOLOG, DROSOPHILA)
x
205745_x_at; 205746_s_at;
213532_at; 237897_at
ADAM METALLOPEPTIDASE DO-
MAIN 17 (TUMOR NECROSIS FAC-
TOR, ALPHA, CONVERTING EN-
ZYME)
x
209905_at; 214651_s_at HOMEOBOX A9 16990763
211277_x_at; 200602_at;
214953_s_at
AMYLOID BETA (A4) PRECUR-
SOR PROTEIN (PEPTIDASE
NEXIN-II, ALZHEIMER DISEASE)
x
239230_at HAIRY AND ENHANCER OF SPLIT
5 (DROSOPHILA)
16990763
221318_at NEUROGENIC DIFFERENTIA-
TION 4
x
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208230_s_at; 208241_at;
206343_s_at; 208232_x_at;
206237_s_at; 208231_at
NEUREGULIN 1 x
213844_at HOMEOBOX A5 16990763
228508_at; 242794_at; 207946_at;
207946_at
MASTERMIND-LIKE 3
(DROSOPHILA)
x
227209_at; 1554784_at; 227202_at;
211203_s_at
CONTACTIN 1 x
212968_at RADICAL FRINGE HOMOLOG
(DROSOPHILA)
17170755
232204_at; 233261_at; 229487_at;
227646_at
EARLY B-CELL FACTOR 1881528
237076_at; 208759_at NICASTRIN 16612405
222022_at; 235721_at; 221835_at;
49051_g_at; 49049_at
DELTEX 3 HOMOLOG
(DROSOPHILA)
x
202182_at GCN5 GENERAL CONTROL OF
AMINO-ACID SYNTHESIS 5-LIKE 2
(YEAST)
x
200792_at; 215308_at X-RAY REPAIR COMPLEMENT-
ING DEFECTIVE REPAIR IN CHI-
NESE HAMSTER CELLS 6 (KU AU-
TOANTIGEN, 70KDA)
x
204369_at; 235980_at; 231854_at PHOSPHOINOSITIDE-3-KINASE,
CATALYTIC, ALPHA POLYPEP-
TIDE
x
227938_s_at; 224215_s_at DELTA-LIKE 1 (DROSOPHILA) x
218839_at; 44783_s_at HAIRY/ENHANCER-OF-SPLIT RE-
LATED WITH YRPW MOTIF 1
x
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211193_at; 211834_s_at;
211195_s_at; 207382_at;
1555581_a_at; 209863_s_at;
211194_s_at
TUMOR PROTEIN P73-LIKE x
209878_s_at; 201783_s_at V-REL RETICULOENDOTHELIO-
SIS VIRAL ONCOGENE HOMOLOG
A, NUCLEAR FACTOR OF KAPPA
LIGHT POLYPEPTIDE GENE
ENHANCER IN B-CELLS 3, P65
(AVIAN)
x
1556015_a_at; 1556014_at MESODERM POSTERIOR 2 HO-
MOLOG (MOUSE)
x
204890_s_at; 204891_s_at LYMPHOCYTE-SPECIFIC PRO-
TEIN TYROSINE KINASE
x
209571_at CBF1 INTERACTING COREPRES-
SOR
x
226499_at SIMILAR TO ANKYRIN-REPEAT
PROTEIN NRARP
16612405
222921_s_at; 219743_at HAIRY/ENHANCER-OF-SPLIT RE-
LATED WITH YRPW MOTIF 2
x
218302_at PRESENILIN ENHANCER 2 HO-
MOLOG (C. ELEGANS)
x
209987_s_at; 209985_s_at;
209988_s_at; 213768_s_at;
209986_at
ACHAETE-SCUTE COMPLEX-
LIKE 1 (DROSOPHILA)
x
244097_at; 205544_s_at COMPLEMENT COMPONENT (3D
EPSTEIN BARR VIRUS) RECEP-
TOR 2
11390591
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209602_s_at; 209603_at;
209604_s_at
GATA BINDING PROTEIN 3 16317090
110
Appendix A
1, General Repository for interaction datasets; 2, Kyoto Encyclopedia of Genes and
Genomes; 3, NetAffx (http://www.affymetrix.com) was screened for array features listed
under the term ’NOTCH signaling pathway’;
5, the pubmed database (http://www.ncbi.nlm.nih.gov/pubmed) was screened for arti-
cles linking genes to NOTCH signaling, unique PUBMED IDs are listed.
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Summary of the Quality Control for Gene Expression Omnibus entry GSE12453.
The results of various quality measurements are summarized below. Especially array
#26 shows several quality problems, yet these are accounted for by the applied pre-
processing procedures.
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Array Name MA Spatial Boxplots Heatmap RLE NUSEplots distribution
GSM312811_pHL ok ok ok ok ok ok
GSM312812_pHL ok ok ok ok ok ok
GSM312813_pHL ok ok ok ok ok ok
GSM312814_pHL ok ok ok ok ok ok
GSM312815_pHL ok ok ok ok ok ok
GSM312816_pHL ok ok ok ok ok ok
GSM312817_pHL ok ok ok ok ok ok
GSM312818_pHL ok * ok ok ok ok
GSM312819_pHL ok ok ok ok ok ok
GSM312820_pHL ok ok ok ok ok ok
GSM312821_pHL ok ok ok ok ok ok
GSM312822_pHL ok * ok ok ok ok
GSM312851_pBL ok ok ok ok ok ok
GSM312853_pBL ok ok ok ok ok ok
GSM312854_pBL ok ok ok ok ok ok
GSM312856_pBL ok ok ok ok ok ok
GSM312857_pBL ok ok ok ok ok ok
GSM312858_pDLBCL ok ok ok ok ok ok
GSM312859_pDLBCL ok ok ok ok ok ok
GSM312860_pDLBCL ok ok ok ok ok ok
GSM312861_pDLBCL ok ok ok ok ok ok
GSM312862_pDLBCL ok ok ok ok ok ok
GSM312863_pDLBCL ok ok ok ok ok ok
GSM312864_pDLBCL ok ok ok ok ok ok
GSM312865_pDLBCL ok ok ok ok ok ok
GSM312867_pDLBCL * ok ok * * ok
GSM312868_pDLBCL ok ok ok ok ok ok
GSM312869_pDLBCL ok ok ok ok ok ok
*, in the marked characteristic, the array differs from all other ones. pHL, primary Hodgkin
Lymphoma sample; pDLBCL, primary Diffuse Large B Cell Lymphoma sample; pBL, primary Burkitt
Lymphoma sample.
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Deregulated NOTCH associated genes in comparisons of different data sets are listed
below (primary sample data, cell line data and merged data). Number codings are
as follows: -1 = significantly up–regulated in cHL; 0 = not significantly regulated in
between the groups; 1 = significantly down–regulated in cHL.
Affymetrix Probe ID Gene Symbol primary data: non-
Hodgkin vs. cHL
cell line data: non-
Hodgkin vs. HRS
merged data: non-
Hodgkin vs. HRS
217094_s_at ITCH 0 0 0
236235_at ITCH 0 0 0
201502_s_at NFKBIA -1 -1 -1
202360_at MAML1 0 0 0
213494_s_at YY1 1 0 0
224711_at YY1 1 0 1
200047_s_at YY1 1 0 1
201901_s_at YY1 1 0 1
201902_s_at YY1 0 0 0
32137_at JAG2 0 0 0
209784_s_at JAG2 0 0 0
241378_at MIB2 0 0 0
228261_at MIB2 1 0 1
241541_at MIB2 1 0 1
226644_at MIB2 0 0 0
241377_s_at MIB2 0 0 0
221036_s_at APH1B 0 0 0
213091_at CRTC1 0 0 0
207159_x_at CRTC1 0 0 0
204863_s_at IL6ST 0 0 0
234967_at IL6ST 0 0 0
234474_x_at IL6ST 0 0 0
212196_at IL6ST 0 -1 -1
211000_s_at IL6ST 0 -1 0
204864_s_at IL6ST 0 0 0
212195_at IL6ST 0 -1 -1
229540_at RBPJ 0 0 0
207785_s_at RBPJ 0 0 0
211974_x_at RBPJ 0 0 -1
204153_s_at MFNG 0 1 1
213783_at MFNG 0 0 0
204152_s_at MFNG 0 1 0
218512_at WDR12 0 0 1
202064_s_at SEL1L 0 -1 -1
202062_s_at SEL1L 0 -1 0
202061_s_at SEL1L 0 -1 -1
230265_at SEL1L 0 -1 0
202063_s_at SEL1L 0 0 0
204849_at TCFL5 0 0 1
235694_at TCFL5 1 0 1
206480_at LTC4S 0 0 0
221315_s_at FGF22 0 0 0
1566814_at FGF22 0 0 0
1566816_at FGF22 0 0 0
209200_at MEF2C 1 1 1
207968_s_at MEF2C 0 1 0
209199_s_at MEF2C 1 1 1
207835_at FBLN1 0 0 0
201787_at FBLN1 0 0 0
202994_s_at FBLN1 0 0 0
207834_at FBLN1 0 0 0
202995_s_at FBLN1 0 0 0
218902_at NOTCH1 0 0 0
223508_at NOTCH1 0 0 0
206759_at FCER2 0 -1 0
206760_s_at FCER2 0 -1 0
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209151_x_at TCF3 0 1 0
213732_at TCF3 0 0 0
215260_s_at TCF3 0 1 1
209152_s_at TCF3 1 1 1
228052_x_at TCF3 0 0 0
213811_x_at TCF3 1 1 1
213730_x_at TCF3 1 1 1
210776_x_at TCF3 1 1 1
213731_s_at TCF3 0 0 0
209153_s_at TCF3 1 1 1
203867_s_at NLE1 0 0 0
203866_at NLE1 0 0 0
208893_s_at DUSP6 0 0 0
208891_at DUSP6 0 0 0
208892_s_at DUSP6 0 0 0
206847_s_at HOXA7 0 0 0
211269_s_at IL2RA -1 -1 -1
206341_at IL2RA 0 -1 0
211148_s_at ANGPT2 0 0 0
236034_at ANGPT2 0 0 0
205572_at ANGPT2 0 0 0
212611_at DTX4 1 1 1
225415_at DTX3L 0 0 0
235106_at MAML2 0 -1 -1
235457_at MAML2 -1 -1 -1
209239_at NFKB1 0 0 0
215270_at LFNG 0 0 0
228762_at LFNG 0 0 0
202604_x_at ADAM10 0 0 -1
214895_s_at ADAM10 0 0 0
204501_at NOV 0 0 0
214321_at NOV 0 0 0
213260_at FOXC1 0 -1 0
1553613_s_at FOXC1 0 0 -1
214722_at NOTCH2NL 0 -1 -1
227067_x_at NOTCH2NL 0 -1 0
209945_s_at GSK3B 0 0 0
1554417_s_at APH1A 0 0 0
218389_s_at APH1A 0 0 0
237327_at APH1A 0 0 0
202284_s_at CDKN1A -1 0 -1
1555186_at CDKN1A 0 0 0
229195_at MESP1 0 0 0
243387_at MESP1 0 0 0
224476_s_at MESP1 0 -1 0
201465_s_at JUN -1 -1 -1
215732_s_at DTX2 0 0 0
226281_at DNER 0 0 0
227678_at XRCC6BP1 0 0 0
1554349_at XRCC6BP1 0 0 0
201996_s_at SPEN 0 0 0
201997_s_at SPEN 0 0 0
1556059_s_at SPEN 0 0 0
1556058_s_at SPEN 0 0 0
211252_x_at PTCRA 0 0 0
211837_s_at PTCRA 0 0 0
215492_x_at PTCRA 0 0 0
218284_at SMAD3 0 1 0
205396_at SMAD3 0 0 0
205398_s_at SMAD3 0 0 0
207538_at IL4 0 0 0
207539_s_at IL4 0 0 0
204262_s_at PSEN2 0 -1 -1
204261_s_at PSEN2 0 -1 0
211373_s_at PSEN2 -1 -1 -1
209097_s_at JAG1 0 0 0
209099_x_at JAG1 0 0 0
216268_s_at JAG1 0 0 0
209098_s_at JAG1 0 0 0
231183_s_at JAG1 0 0 0
213147_at HOXA10 0 0 0
213150_at HOXA10 0 -1 0
224726_at MIB1 0 0 0
224722_at MIB1 0 1 0
236573_at MIB1 0 0 0
224720_at MIB1 0 0 0
224725_at MIB1 0 0 0
1558645_at MIB1 0 0 0
203237_s_at NOTCH3 0 0 0
203238_s_at NOTCH3 0 0 0
215205_x_at NCOR2 0 0 0
208888_s_at NCOR2 0 0 0
207760_s_at NCOR2 0 0 0
208889_s_at NCOR2 0 0 0
215424_s_at SNW1 0 0 0
201575_at SNW1 0 0 0
207195_at CNTN6 0 0 0
230568_x_at DLL3 0 0 0
219537_x_at DLL3 0 0 0
229755_x_at DLL3 0 0 0
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222898_s_at DLL3 0 1 0
212349_at POFUT1 0 0 0
210433_at POFUT1 0 0 0
203460_s_at PSEN1 0 0 0
207782_s_at PSEN1 0 -1 0
238816_at PSEN1 0 0 0
226577_at PSEN1 0 -1 0
1559206_at PSEN1 0 0 0
203845_at KAT2B 0 0 0
239585_at KAT2B 0 0 0
235858_at CREBBP 0 0 0
202160_at CREBBP 0 0 0
211808_s_at CREBBP 0 0 0
212377_s_at NOTCH2 0 -1 -1
210756_s_at NOTCH2 0 -1 0
202445_s_at NOTCH2 0 -1 -1
202443_x_at NOTCH2 0 -1 -1
224548_at HES7 0 -1 0
208292_at BMP10 0 0 0
227347_x_at HES4 0 0 0
223525_at DLL4 0 0 0
227336_at DTX1 1 1 1
207946_at MAML3 0 0 0
220662_s_at HEYL 0 0 0
226828_s_at HEYL 0 0 0
203394_s_at HES1 0 0 0
203395_s_at HES1 0 0 0
203393_at HES1 0 0 0
209073_s_at NUMB 0 0 0
236930_at NUMB 0 0 -1
207545_s_at NUMB 0 -1 0
230462_at NUMB 0 0 0
221333_at FOXP3 0 0 0
221334_s_at FOXP3 0 0 0
224211_at FOXP3 0 0 0
205247_at NOTCH4 0 0 0
240786_at NOTCH4 0 0 0
210948_s_at LEF1 0 1 0
221558_s_at LEF1 0 1 0
221557_s_at LEF1 0 1 0
211370_s_at MAP2K5 0 0 0
211371_at MAP2K5 0 0 0
218751_s_at FBXW7 0 0 0
229419_at FBXW7 0 0 0
222729_at FBXW7 0 0 0
205745_x_at ADAM17 0 0 0
205746_s_at ADAM17 0 0 0
213532_at ADAM17 0 0 0
237897_at ADAM17 0 0 0
209905_at HOXA9 0 0 0
214651_s_at HOXA9 0 0 0
211277_x_at APP 0 0 0
200602_at APP 0 1 0
214953_s_at APP 0 1 0
239230_at HES5 0 0 0
221318_at NEUROD4 0 0 0
208230_s_at NRG1 0 0 0
208241_at NRG1 0 0 0
206343_s_at NRG1 0 0 0
208232_x_at NRG1 0 0 0
206237_s_at NRG1 0 0 0
208231_at NRG1 0 0 0
213844_at HOXA5 0 0 0
228508_at MAML3 0 0 0
242794_at MAML3 0 0 0
207946_at MAML3 0 0 0
227209_at CNTN1 0 0 0
1554784_at CNTN1 0 0 0
227202_at CNTN1 0 0 0
211203_s_at CNTN1 0 0 0
212968_at RFNG 1 0 0
232204_at EBF1 0 1 1
233261_at EBF1 0 1 1
229487_at EBF1 0 1 1
227646_at EBF1 0 1 0
237076_at NCSTN 0 0 0
208759_at NCSTN 0 0 0
222022_at DTX3 0 0 0
235721_at DTX3 0 0 0
221835_at DTX3 0 0 0
49051_g_at DTX3 0 0 0
49049_at DTX3 0 0 0
202182_at KAT2A 1 0 0
200792_at XRCC6 0 0 0
215308_at XRCC6 0 0 0
204369_at PIK3CA 0 0 0
235980_at PIK3CA 0 0 0
231854_at PIK3CA 0 0 0
227938_s_at DLL1 0 0 0
224215_s_at DLL1 0 0 0
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218839_at HEY1 0 0 0
44783_s_at HEY1 0 0 -1
211834_s_at TP63 0 0 0
211195_s_at TP63 0 0 0
207382_at TP63 0 0 0
1555581_a_at TP63 0 0 0
209863_s_at TP63 0 0 0
211194_s_at TP63 0 -1 0
209878_s_at RELA 0 0 0
201783_s_at RELA 0 0 0
1556015_a_at MESP2 0 0 0
1556014_at MESP2 0 0 0
204890_s_at LCK 0 1 1
204891_s_at LCK 0 1 1
209571_at CIR1 0 0 0
226499_at NRARP 0 0 0
222921_s_at HEY2 0 0 0
219743_at HEY2 0 0 0
218302_at PSENEN 0 0 0
209987_s_at ASCL1 0 0 0
209985_s_at ASCL1 0 0 0
209988_s_at ASCL1 0 0 0
213768_s_at ASCL1 0 0 0
209986_at ASCL1 0 0 0
244097_at CR2 0 0 0
205544_s_at CR2 0 0 0
209602_s_at GATA3 0 -1 -1
209603_at GATA3 0 -1 -1
209604_s_at GATA3 -1 -1 -1
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The 10 Keyorganics compounds identified by vHTS to bind to CSL, were initially tested
using the NOTCH-reporter assay described above, using HEK293 cells as test systems.
Compounds dissolved in DMSO or DMSO only were administered 2 hours after trans-
fection of the reporter constructs. Results are shown below.
Keyorganics accession
number
concentration luciferase ratio standard deviation
12R-0816 100 µM 2.12 0.01
12R-0816 10 µM 3.66 0.06
12R-0816 1 µM 3.70 0.12
12R-0816 0.1 µM 3.11 0.09
12R-1182 100 µM 8.19 0.25
12R-1182 10 µM 3.85 0.02
12R-1182 1 µM 3.42 0.81
12R-1182 0.1 µM 3.55 0.05
3R-0256 100 µM 4.01 0.08
3R-0256 10 µM 3.82 0.10
3R-0256 1 µM 3.92 0.06
3R-0256 0.1 µM 3.57 0.09
3R-0688 100 µM 3.87 0.20
3R-0688 10 µM 3.78 0.45
3R-0688 1 µM 2.77 1.64
3R-0688 0.1 µM 3.58 0.41
3K-521S 100 µM 2.96 0.42
3K-521S 10 µM 4.11 0.03
3K-521S 1 µM 4.38 0.25
3K-521S 0.1 µM 3.08 1.83
6M-003 100 µM 1.44 0.47
6M-003 10 µM 2.79 1.63
6M-003 1 µM 3.20 1.96
6M-003 0.1 µM 2.47 1.31
10B-035 100 µM 3.22 0.04
10B-035 10 µM 3.39 0.13
10B-035 1 µM 3.31 0.12
10B-035 0.1 µM 2.99 0.09
10B-049 100 µM 4.36 0.04
10B-049 10 µM 3.72 0.06
10B-049 1 µM 3.20 0.07
10B-049 0.1 µM 3.41 0.08
10E-23 100 µM 3.12 0.08
10E-23 10 µM 3.82 0.08
10E-23 1 µM 3.38 0.11
10E-23 0.1 µM 3.20 0.08
12P-818 100 µM 2.94 0.09
12P-818 10 µM 3.83 0.08
12P-818 1 µM 3.21 0.12
12P-818 0.1 µM 3.35 0.03
DMSO 10/00 3.34 0.08
DMSO 10/00 3.29 0.06
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Below, a Mascot Search Result report identifying our purified protein to be human CSL
is attached. Note: SUH_human is synonymous with human CSL.
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Mascot Search Results
Protein View
Match to: SUH_HUMAN Score: 744
Recombining binding protein suppressor of hairless - Homo sapiens (Human)
Found in search of MSC388.pkl
Nominal mass (Mr): 55628; Calculated pI value: 6.80
NCBI BLAST search of SUH_HUMAN against nr
Unformatted sequence string for pasting into other applications
Taxonomy: Homo sapiens
Variable modifications: Carbamidomethyl (C),Oxidation (M),Propionamide (C)
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P
Sequence Coverage: 23%
Matched peptides shown in Bold Red
1 MDHTEGLPAE EPPAHAPSPG KFGERPPPKR LTREAMRNYL KERGDQTVLI
51 LHAKVAQKSY GNEKRFFCPP PCVYLMGSGW KKKKEQMERD GCSEQESQPC
101 AFIGIGNSDQ EMQQLNLEGK NYCTAKTLYI SDSDKRKHFM LSVKMFYGNS
151 DDIGVFLSKR IKVISKPSKK KQSLKNADLC IASGTKVALF NRLRSQTVST
201 RYLHVEGGNF HASSQQWGAF FIHLLDDDES EGEEFTVRDG YIHYGQTVKL
251 VCSVTGMALP RLIIRKVDKQ TALLDADDPV SQLHKCAFYL KDTERMYLCL
301 SQERIIQFQA TPCPKEPNKE MINDGASWTI ISTDKAEYTF YEGMGPVLAP
351 VTPVPVVESL QLNGGGDVAM LELTGQNFTP NLRVWFGDVE AETMYRCGES
401 MLCVVPDISA FREGWRWVRQ PVQVPVTLVR NDGIIYSTSL TFTYTPEPGP
451 RPHCSAAGAI LRANSSQVPP NESNTNSEGS YTNASTNSTS VTSSTATVVS
501
 Residue Number Increasing Mass Decreasing Mass 
Start - End Observed Mr(expt) Mr(calc) Delta Miss Sequence
42 - 54 493.94 1478.79 1478.82 -0.03 1 K.ERGDQTVLILHAK.V
(Ions score 37)
44 - 54 398.87 1193.60 1193.68 -0.08 0 R.GDQTVLILHAK.V
(Ions score 41)
44 - 54 597.83 1193.65 1193.68 -0.03 0 R.GDQTVLILHAK.V
(Ions score 41)
127 - 136 399.83 1196.47 1196.60 -0.13 1 K.TLYISDSDKR.K
(Ions score 56)
127 - 136 599.26 1196.51 1196.60 -0.09 1 K.TLYISDSDKR.K
(Ions score 65)
138 - 144 431.21 860.42 860.46 -0.04 0 K.HFMLSVK.M (Ions
score 43)
145 - 159 846.81 1691.61 1691.79 -0.18 0 K.MFYGNSDDIGVFLSK.R
(Ions score 100)
145 - 159 846.90 1691.79 1691.79 0.00 0 K.MFYGNSDDIGVFLSK.R
(Ions score 29)
145 - 159 846.90 1691.79 1691.79 0.00 0 K.MFYGNSDDIGVFLSK.R
(Ions score 64)
145 - 159 846.90 1691.79 1691.79 0.00 0 K.MFYGNSDDIGVFLSK.R
(Ions score 67)
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145 - 159 846.90 1691.79 1691.79 0.01 0 K.MFYGNSDDIGVFLSK.R
(Ions score 49)
145 - 159 846.91 1691.80 1691.79 0.02 0 K.MFYGNSDDIGVFLSK.R
(Ions score 16)
239 - 249 640.78 1279.54 1279.62 -0.08 0 R.DGYIHYGQTVK.L
(Ions score 51)
250 - 261 631.86 1261.70 1261.65 0.05 0 K.LVCSVTGMALPR.L
Oxidation (M) (Ions score 5)
270 - 285 584.28 1749.81 1749.89 -0.08 0 K.QTALLDADDPVSQLHK.C
(Ions score 88)
316 - 335 750.36 2248.05 2248.07 -0.02 1
K.EPNKEMINDGASWTIISTDK.A (Ions score 68)
320 - 335 890.92 1779.82 1779.83 -0.01 0 K.EMINDGASWTIISTDK.A
(Ions score 113)
320 - 335 890.93 1779.84 1779.83 0.00 0 K.EMINDGASWTIISTDK.A
(Ions score 17)
320 - 335 890.93 1779.84 1779.83 0.01 0 K.EMINDGASWTIISTDK.A
(Ions score 18)
320 - 335 890.93 1779.84 1779.83 0.01 0 K.EMINDGASWTIISTDK.A
(Ions score 36)
384 - 396 801.84 1601.66 1601.72 -0.06 0 R.VWFGDVEAETMYR.C
(Ions score 71)
384 - 396 534.91 1601.69 1601.72 -0.02 0 R.VWFGDVEAETMYR.C
(Ions score 16)
384 - 396 801.86 1601.70 1601.72 -0.02 0 R.VWFGDVEAETMYR.C
(Ions score 88)
384 - 396 801.87 1601.72 1601.72 -0.00 0 R.VWFGDVEAETMYR.C
(Ions score 67)
384 - 396 801.87 1601.72 1601.72 0.00 0 R.VWFGDVEAETMYR.C
(Ions score 75)
384 - 396 801.87 1601.72 1601.72 0.00 0 R.VWFGDVEAETMYR.C
(Ions score 69)
384 - 396 801.87 1601.72 1601.72 0.00 0 R.VWFGDVEAETMYR.C
(Ions score 68)
384 - 396 801.87 1601.72 1601.72 0.00 0 R.VWFGDVEAETMYR.C
(Ions score 62)
384 - 396 809.86 1617.71 1617.71 -0.01 0 R.VWFGDVEAETMYR.C
Oxidation (M) (Ions score 59)
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Exemplary ITC measurement for compound 6M-003 and purified, recombinant, human
CSL. Note, that no binding saturation takes place, indicating, that compound 6M-003
does not specifically bind to CSL.
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Abbreviations
SI units are not stated.
Abbreviation Explanation
AA amino acid
bp base pairs
B-ALL B cell acute lymphoblastic leukemia
BCA bicinchoninic acid
BD binding domain
BL Burkitt’s lymphoma
BME β-mercaptoethanol
cHL classical Hodgkin lymphoma
cpm counts per minute
CT cycle threshold
Da Dalton
DAPT N-[N-(3,5-Difluoro-phenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester
DLBCL diffuse large B cell lymphoma
DNA Deoxyribonucleic acid
dNTP deoxynucleotide triphosphate
DTT dithiotreitol
e.g. exempli gratia
EBV Epstein Barr virus
EDTA ethylenediaminetetraacetate
EMSA electrophoretic mobility shift assay
FACS fluorescence activated cell sorting
FPLC fast protein liquid chromatography
g gravity
GFP green fluorescent protein
GO gene ontology
GSEA Gene Set Enrichment Analysis
GSI γ-secretase inhibitor
HD heterodimerization domain
HRS Hodgkin Reed Sternberg
HPLC high-performance liquid chromatography
ITC isothermal titration calorimetry
IPTG Isopropyl-β-D-thiogalactopyranoside
MAML Mastermind-like
MCL Mantle cell lymphoma
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Abbreviations
min minutes
mRNA messenger ribonucleic acid
NIC NOTCH intracellular domain
n.s. not significant
NTC NOTCH transcriptional complex
NUSE normalized unscaled standard error
p probability
PBS phosphate buffered saline
PCA principal components analysis
PCR polymerase-chain-reaction
PDB protein data bank
qPCR quantitative PCR
RLE relative log expression
RNA ribonucleic acid
RT room temperature
RT-PCR reverse transcriptase PCR
sd standard deviation
SDS-PAGE Sodiumdodecylsulfate-polyacrylamide gel electrophoresis
sec seconds
SEC size exclusion chromatography
sqPCR semi-quantitative PCR
T-ALL T cell acute lymphoblastic leukemia
TAD transactivation domain
TBE Tris Borate EDTA
TBS Tris buffered saline
Tris tris(hydroxymethyl)aminomethane
U Units
vHTS virtual high throughput screen
WB western blotting
WHO World Health Organization
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